![]() |
![]() |
![]() |
![]() |
306-P | PAX5 DEFICIENCY AND GERMLINE SUSCEPTIBILITY TO PEDIATRIC LEUKEMIA | Franziska Auer | ![]() |
![]() |
|||
307-P | DEL(17)(Q11) IS TYPICAL MARKER OF IMMATURE T-ALL OF ADULTS, WITH NF1, UTP6, AND SUZ12 HAPLOINSUFFICIENCY, GENOME INSTABILITY, AND GENE DOWNREGULATION | Valentina Bardelli | ![]() |
![]() |
|||
310-P | BH3 PROFILING IDENTIFIES SELECTIVE BCL-2 DEPENDENCE OF ADULT EARLY T-CCELL PROGENITOR AND TYPICAL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS | Shruti Bhatt | ![]() |
![]() |
|||
313-P | RECURRENT PATHOGENIC GERMLINE CHEK2 VARIANTS IN PEDIATRIC PATIENTS WITH HEMATOLOGICAL MALIGNANCIES | Triantafyllia Brozou | ![]() |
![]() |
|||
314-P | THERAPEUTICALLY TARGETING THE UNIQUE BARCODE OF MLL/AF4 | Rachel Cameron | ![]() |
![]() |
|||
316-P | THE ROLE OF TET2 IN (PRE)-LEUKEMIC T-ALL: TET2 TO THE RESCUE? | Stien De Coninck | ![]() |
![]() |
|||
317-P | TARGETING HYPERACTIVE PDGFR-B IN T-ALL AND T-LBL | Stien De Coninck | ![]() |
![]() |
|||
318-P | A DUAL ROLE FOR PSIP1 IN T-ALL | Lisa Demoen | ![]() |
![]() |
|||
320-P | TCF3-PBX1 LEUKEMIA INVADES IPSC-DERIVED CEREBRAL ORGANOIDS | Philip Gebing | ![]() |
![]() |
|||
324-P | PHARMACOLOGIC INHIBITION OF DYRK1A RENDERS HIGH-RISK KMT2A-R ALL SENSITIVE TO VENETOCLAX | Christian Hurtz | ![]() |
![]() |
|||
333-P | MULTI-COHORT GENE EXPRESSION RESOURCE FOR AUTOMATIC SUBTYPING OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Ville-Petteri Mäkinen | ![]() |
![]() |
|||
337-P | LONG TERM INFECTION-DRIVES CHANGES IN THE BONE MARROW MICRO-ENVIRONMENT OF PAX5+/- MICE PREDISPOSED TO B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA | Aleksandra Pandyra | ![]() |
![]() |
|||
340-P | IN VITRO AND IN VIVO EFFICACY OF A NOVEL KINASE INHIBITOR TARGETING JAK2 GENE REARRANGEMENTS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA | Manuel Quadri | ![]() |
![]() |
|||
344-P | THE DUAL BCL-2 AND BCL-XL INHIBITOR AZD4320 SHOWS ON-TARGET ACTIVITY IN ALL AND ACTS SYNERGISTICALLY WITH MCL-1 INHIBITION | Felix Seyfried | ![]() |
![]() |
|||
347-P | COOPERATION OF TLX3 AND FLT3-ITD IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IS ENHANCED BY TLE4 INACTIVATION | Quentin Van Thillo | ![]() |
![]() |
|||
348-P | MRK-560 AND DEXAMETHASONE ARE SYNERGISTIC IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Charlien Vandersmissen | ![]() |
![]() |
|||
353-P | FORTY MONTHS UPDATE OF THE GIMEMA LAL2116 (D-ALBA) PROTOCOL AND ANCILLARY LAL2217 STUDY FOR NEWLY DIAGNOSED ADULT PH+ ALL | Sabina Chiaretti | ![]() |
![]() |
|||
355-P | MINI-HYPER-CVD PLUS INOTUZUMAB OZOGAMICIN, WITH OR WITHOUT BLINATUMOMAB, IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATES FROM A PHASE II TRIAL | Fadi Haddad | ![]() |
![]() |
|||
357-P | MULTICENTER RETROSPECTIVE ANALYSIS OF CLINICAL OUTCOME OF ADULT PATIENS WITH MIXED-PHENOTYPE ACUTE LEUKEMIA (MPAL) DIAGNOSED AND TREATED IN THE LAST TEN YEARS. A CAMPUS-ALL STUDY. | Davide Lazzarotto | ![]() |
![]() |
|||
359-P | IMPROVED OVERALL SURVIVAL AND MRD CLEARANCE WITH BLINATUMOMAB VS CHEMOTHERAPY AS PRE-TRANSPLANT CONSOLIDATION IN PEDIATRIC HIGH-RISK FIRST-RELAPSE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) | Franco Locatelli | ![]() |
![]() |
|||
361-P | EARLY MEASURABLE RESIDUAL DISEASE ANALYSIS IS ONLY PREDICTIVE OF SURVIVAL OUTCOMES AFTER TWO CYCLES OF TREATMENT IN ADULTS WITH B-LYMPHOBLASTIC LEUKEMIA RECEIVING HYPER-CVAD INDUCTION. | Rithin Nedumannil | ![]() |
![]() |
|||
365-P | INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL) | Farhad Ravandi | ![]() |
![]() |
|||
368-P | A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Jayastu Senapati | ![]() |
![]() |
|||
369-P | A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA | Jayastu Senapati | ![]() |
![]() |
|||
371-P | HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA | Nicholas Short | ![]() |
![]() |
|||
372-P | DISMAL OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AFTER FAILURE OF BOTH INOTUZUMAB OZOGAMICIN AND BLINATUMOMAB | Walid Macaron | ![]() |
![]() |
|||
373-P | CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND METABOLIC FACTORS IN CHILDHOOD CANCER SURVIVORS | Emmanouil Athanasopoulos | ![]() |
![]() |
|||
374-P | BLINATUMOMAB AS CONSOLIDATION FOR ADULT B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. A REAL-WORLD STUDY | Irene Urbino | ![]() |
![]() |
|||
377-P | GENETIC CHARACTERISTICS AND CD7-CAR-T THERAPY OF TRAD::MYC TRANSLOCATION POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS | Hongxing Liu | ![]() |
![]() |
|||
380-P | EX VIVO IMMUNE ACTIVATION WITH THE MACROPHAGE-TARGETING IMMUNOTHERAPY, ANTI-CLEVER-1 ANTIBODY BEXMARILIMAB, IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME | Sofia Aakko | ![]() |
![]() |
|||
383-P | USING CF-DNA AS STARTING MATERIAL FOR MRD STUDIES BY NGS IMPROVES THE SENSITIVITY OF THE METHOD AGAINST CTCS. | Noemí Álvarez Sánchez-Redondo | ![]() |
![]() |
|||
385-P | DETECTION OF KMT2A PARTIAL TANDEM DUPLICATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS BY NGS | Alícia Artigas-Baleri | ![]() |
![]() |
|||
387-P | UNRAVELING LEUKEMIC STEM CELLS MITOCHONDRIAL DEPENDENCY IN PEDIATRIC ACUTE MYELOID LEUKEMIA | Maddalena Benetton | ![]() |
![]() |
|||
390-P | ACUTE MYELOID LEUKEMIA SUPPRESSION BY PALBOCICLIB AND PONATINIB IN PATIENT-DERIVED XENOGRAFT | Daniel Busa | ![]() |
![]() |
|||
391-P | FLT3-ITD MEASUREMENT AT DIAGNOSIS AND FOR THE ASSESSMENT OF MINIMAL RESIDUAL DISEASE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA: CDNA VS. DNA | Diego Carbonell | ![]() |
![]() |
|||
397-P | PROLACTIN RECEPTOR CONFERS CHEMORESISTANCE DUE TO SENESCENCE ENTRANCE IN ACUTE MYELOID LEUKEMIA | Laia Cuesta-Casanovas | ![]() |
![]() |
|||
398-P | DEVELOPMENT AND CHARACTERIZATION OF PRECLINICAL IN VIVO MODELS FOR THE IDENTIFICATION AND TESTING OF NEW THERAPEUTIC APPROACHES FOR PEDIATRIC ACUTE MYELOID LEUKEMIA | Ambra Da Ros | ![]() |
![]() |
|||
403-P | PROGNOSTIC SIGNIFICANCE OF LONG NON-CODING RNA GAS5 AND MICRORNA-222 EXPRESSION PROFILES IN YOUNGER AML PATIENTS | Đorde Pavlovic | ![]() |
![]() |
|||
409-P | NPM1 MUTATED SAMPLES ARE ESPECIALLY VULNERABLE WHEN TARGETING RAC1 IN PATIENT-DERIVED AML CELLS IN VITRO | Anette Hemsing | ![]() |
![]() |
|||
415-P | TARGETED 3RD-GENERATION (NANOPORE) SEQUENCING REVEALS MANY NOVEL CIRCULAR RNAS OF THE APOPTOSIS-RELATED BCL2L12 GENE, EXPRESSED IN HUMAN CELLS FROM ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES | Christos Kontos | ![]() |
![]() |
|||
416-P | CLONAL HEMATOPOIESIS IS COMMON IN AML LONG-TERM SURVIVORS AND MAY ASSOCIATE WITH DIABETES AND SECONDARY NEOPLASIAS, BUT NOT OTHER HEALTH OUTCOMES | Simon M. Krauß | ![]() |
![]() |
|||
417-P | A SINGLE AMINO ACID AT THE PNT DOMAIN OF ERG MEDIATES ITS LEUKEMOGENIC ACTIVITY THROUGH INTERACTION WITH THE NCOR-HDAC3 CO-REPRESSOR COMPLEX. | Eitan Kugler | ![]() |
![]() |
|||
420-P | FORCING LEUKAEMIC STEM CELL TO LEAVE QUIESCENT STATE BY INHIBITING HEDGEHOG, NOTCH AND WNT/BETA-CATENIN SIGNALLING PATHWAYS | Daniel Láinez-González | ![]() |
![]() |
|||
425-P | ROLE OF LYSOSOMAL-ASSOCIATED GENE LAPMT4B IN LEUKEMIA | Jennifer Delgado-Martínez | ![]() |
![]() |
|||
426-P | A SINGLE-CENTER RETROSPECTIVE ANALYISIS OF THE MUTATIONAL PROFILE IN ACUTE MYELOID LEUKEMIA PATIENTS | Yolanda Martínez Díez | ![]() |
![]() |
|||
429-P | CLONALLY RESOLVED SINGLE-CELL MULTI-OMICS IDENTIFIES LEUKEMIA SURFACE ANTIGENS | Anne Kathrin Merbach | ![]() |
![]() |
|||
430-P | MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB AZACITIDINE COMPARED TO PLACEBO AZACITIDINE | Steve Waye | ![]() |
![]() |
|||
432-P | RISK STRATIFICATION IN ACUTE MYELOID LEUKEMIA: EXTERNAL VALIDATION OF THE STELLAE-123 GENE EXPRESSION MODEL AND COMPARISON WITH CURRENT PROGNOSTIC SCORES | Andres Peleteiro Raindo | ![]() |
![]() |
|||
434-P | MITOCONDRIAL MCL1 REGULATES LEUKEMIC CELLS METABOLISM VIA DIRECT INTERACTION WITH HEXOKINASE II. METABOLIC SIGNATURE AT ONSET PREDICTS OVERALL SURVIVAL IN AMLS´ PATIENTS | Nelida Ines Noguera | ![]() |
![]() |
|||
435-P | ANALYSIS OF MYELOBLAST IMMUNOPHENOTYPE PROFILE IN ACUTE MYELOID LEUKAEMIA AS PREDICTOR FOR CLINICAL OUTCOME | Mateusz Nowak | ![]() |
![]() |
|||
436-P | TARGETED DELIVERY OF T22-PE24-H6 TO CXCR4 POSITIVE CELLS FOR ACUTE MYELOID LEUKEMIA TREATMENT | Yáiza Núńez Amela | ![]() |
![]() |
|||
438-P | ARYL HYDROCARBON RECEPTOR SIGNALLING IN NORMAL HAEMATOPOIETIC (HSC) AND LEUKEMIA STEM CELLS (LSC): DIFFERENTIAL EFFECT OF AHR ANTAGONIST ON LSC COMPARED TO HSC | Alyona Oryshchuk | ![]() |
![]() |
|||
439-P | ASSOCIATING EX VIVO DRUG SENSITIVITY WITH METABOLIC STATUS IDENTIFIES EFFECTIVE COMBINATION STRATEGIES IN ACUTE MYELOID LEUKEMIA | Diego A Pereira-Martins | ![]() |
![]() |
|||
440-P | THE COMBINATION VENETOCLAX PLUS MCL1 OVERCOMES DRUG RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA | Diego A Pereira-Martins | ![]() |
![]() |
|||
443-P | IMPACT OF PHARMACOGENETIC VARIANTS ON CYTARABINE AND ANTHRACYCLINE EFFECT ON OUTCOMES IN ADULT AML PATIENTS | Zlatko Pravdic | ![]() |
![]() |
|||
444-P | IDENTIFICATION OF FUNCTIONAL GENETIC DEPENDENCIES IN CEBPA-MUTATED ACUTE MYELOID LEUKEMIA | Ludovica Proietti | ![]() |
![]() |
|||
445-P | CRYPTIC TRANSLOCATION T(5;11)(Q35;P15) RESULTING IN NUP98::NSD1 GENE FUSION IN ADULTS WITH DE NOVO ACUTE MYELOID LEUKEMIA (AML) | Sarka Ransdorfova | ![]() |
![]() |
|||
446-P | USE OF MIRNA EXPRESSION PATTERNS REVEALS ACTIVIN RECEPTOR 2 PATHWAY IN MEDIATING CHEMO-RESISTANT AML | Paula Reichelt | ![]() |
![]() |
|||
447-P | BCL2-INHIBITION TARGETS LEUKEMIC STEM CELLS IN ACUTE MYELOID LEUKEMIA INDEPENDENT OF MONOCYTIC BLAST POPULATIONS | Simon Renders | ![]() |
![]() |
|||
448-P | PROGNOSTIC IMPACT OF SOMATIC CEBPA BZIP DOMAIN MUTATIONS IN ACUTE MYELOID LEUKEMIA | Frank G. Ruecker | ![]() |
![]() |
|||
453-P | CDK6 DEGRADATION IS IMPEDED BY P16INK4A AND P18INK4C IN AML | Belinda Schmalzbauer | ![]() |
![]() |
|||
454-P | VENETOCLAX AND GILTERITINIB SYNERGIZE IN FLT3 WILDTYPE ACUTE MYELOID LEUKEMIA BY SUPPRESSION OF MCL-1 VIA COMBINED AXL AND FLT3 TARGETING | Christina Schmidt | ![]() |
![]() |
|||
455-P | BREAKING THE PUMP: TARGETING THE SODIUM-POTASSIUM PUMP AS A THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKEMIA | Constanze Schneider | ![]() |
![]() |
|||
460-P | RECOMBINANT SLIT2 INHIBITS ACUTE MYELOID LEUKEMIA CELL PROLIFERATION IN VITRO AND IN VIVO | Luise Araujo De Albuquerque Simoes | ![]() |
![]() |
|||
461-P | MYELOID KINOME INHIBITOR HM43239 OVERCOMES ACQUIRED RESISTANCE IN ACUTE MYELOID LEUKEMIA MODELS | Rafael Bejar | ![]() |
![]() |
|||
463-P | RE-PURPOSING OF GENE SIGNATURES IN AML UNCOVERS NOVEL ENERGETICS-ASSOCIATED MOLECULAR SUBTYPES | Paul Strain | ![]() |
![]() |
|||
464-P | COMPARED TO CLASSICAL CYTOGENETICS OPTICAL GENOME MAPPING (OGM) DETECTS MULTIPLE ADDITIONAL STRUCTURAL CHROMOSOMAL ABERRATIONS IN PEDIATRIC ACUTE MYELOID LEUKEMIA (AML) | Julia Suttorp | ![]() |
![]() |
|||
465-P | A LIPID NANOPARTICLE DELIVERY SYSTEM FOR TARGETING THE LEUKAEMIC FUSION GENE RUNX1/ETO BY SIRNA | Laura Swart | ![]() |
![]() |
|||
467-P | FUNCTIONAL CHARACTERIZATION OF ABERRANT GATA1 PROTEIN COMPLEXES IN NORMAL AND MALIGNANT HUMAN ERYTHROBLASTS | Samantha Tauchmann | ![]() |
![]() |
|||
468-P | MRD AS A BIOMARKER FOR RESPONSE TO DONOR LYMPHOCYTE INFUSION AFTER AL-LOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MYELOID LEUKEMIA | Katrin Teich | ![]() |
![]() |
|||
472-P | THE FLT3-ITD RECEPTOR CAN PROMOTE PROTEIN FOLDING IN THE ENDOPLASMIC RETICULUM THROUGH THE OXIDOREDUCTASE ERO1 | Maria Turos Cabal | ![]() |
![]() |
|||
473-P | DEVELOPMENT OF POTENTIAL BIOMARKERS FOR IRAK4 INHIBITOR EMAVUSERTIB IN HUMAN ACUTE MYELOID LEUKEMIA | Andrey Ugolkov | ![]() |
![]() |
|||
474-P | PIEZO1 AND THE THERAPEUTIC POTENTIAL OF MECHANORECEPTORS IN ACUTE MYELOID LEUKAEMIA | Maria Velasco Estevez | ![]() |
![]() |
|||
476-P | LOSS OF CHD4 IN ACUTE MYELOID LEUKAEMIA GIVES RISE TO INCREASED DNA DAMAGE REPAIR DEFECTS AND ALTERED CELL CYCLE PROGRESSION | Déirdra Venney | ![]() |
![]() |
|||
478-P | THE GERMLINE VARIANT GFI1-36N PROMOTES GENETIC INSTABILITY IN LEUKEMIC CELLS AND OPENS NEW THERAPEUTIC APPROACHES FOR ABOUT 15% OF ALL AML PATIENTS | Jan Vorwerk | ![]() |
![]() |
|||
479-P | DNA METHYLATION PROFILING REFINES THE PROGNOSTIC CLASSIFICATION OF ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH INTENSIVE CHEMOTHERAPY | Sebastian Vosberg | ![]() |
![]() |
|||
480-P | NKG2D-MEDIATED ANTI-TUMOR IMMUNITY CONTRIBUTES TO THE FAVORABLE PROGNOSIS IN APL | Huaiyu Wang | ![]() |
![]() |
|||
487-P | SMALL NON-CODING RNAS ASSOCIATE WITH CHROMATIN TO MAINTEIN PROPOGATION OF ACUTE MEYLOID LEUKEMIA | Haiyang Yun | ![]() |
![]() |
|||
488-P | THZ1, A COVALENT CDK7 INHIBITOR, INDUCES APOPTOSIS IN ACUTE MYELOID LEUKEMIA CELLS AND EXERTS SYNERGISTIC ANTILEUKEMIA ACTIVITY WITH AZACITIDINE | Shuai Zhang | ![]() |
![]() |
|||
491-P | PREDICTIVE FACTORS OF DIFFERENTIATION SYNDROME IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA | Mariem Ben Salah | ![]() |
![]() |
|||
492-P | TAMIBAROTENE IN COMBINATION WITH VENETOCLAX AND AZACITIDINE IN PREVIOUSLY UNTREATED ADULT PATIENTS SELECTED FOR RARA-POSITIVE AML WHO ARE INELIGIBLE FOR STANDARD INDUCTION THERAPY (SELECT AML-1) | Eytan Stein | ![]() |
![]() |
|||
504-P | CLINICAL MUTATIONAL ANALYSIS BY NEXT-GENERATION SEQUENCING AND REAL-LIFE VALIDATION OF THE REVISED 2017 EUROPEAN LEUKEMIANET GENETIC RISK STRATIFICATION IN AML PATIENTS | Clara Aparicio Pérez | ![]() |
![]() |
|||
508-P | REAL LIFE EXPERIENCE USING FRONT-LINE CPX-351 FOR THERAPY-RELATED AND AML-MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY. | Teresa Bernal | ![]() |
![]() |
|||
509-P | CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION | Lara Bischof | ![]() |
![]() |
|||
518-P | PEDAL/EUPAL INTERNATIONAL COLLABORATION TO IMPROVE THE OUTCOME OF CHILDREN WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA | Valeria Ceolin | ![]() |
![]() |
|||
528-P | A MIRNA SIGNATURE RELATED TO STEMNESS IDENTIFIES HIGH-RISK PATIENTS IN PEDIATRIC ACUTE MYELOID LEUKEMIA | Elena Esperanza Cebollada | ![]() |
![]() |
|||
530-P | TAGRAXOFUSP IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM WITH/WITHOUT CENTRAL NERVOUS SYSTEM INVOLVEMENT AND INTRATHECAL CHEMOTHERAPY AS PRIMARY TREATMENT OR PROPHYLAXIS: AN ITALIAN EXPERIENCE. | Giulia Rivoli | ![]() |
![]() |
|||
532-P | ACUTE MYELOID LEUKEMIA (AML): UNICENTRIC REPORT ON 1029 PATIENTS DIAGNOSED IN TERTIAL REFERAL CENTER | Anne Fricke | ![]() |
![]() |
|||
534-P | AZACITIDINE PLUS VENETOCLAX FOR THE TREATMENT OF RELAPSED AND FIRST-LINE AML PATIENTS | Sylvain Garciaz | ![]() |
![]() |
|||
535-P | UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD). | Bruno Garibaldi | ![]() |
![]() |
|||
536-P | VALUE OF MEASURABLE RESIDUAL DISEASE BY MULTIPARAMETRIC FLOW CYTOMETRY IN NON-PROMYELOCYTIC ACUTE MYELOID LEUKEMIA. REAL WORLD EVIDENCE | Alberto Daniel Gimenez Conca | ![]() |
![]() |
|||
537-P | SURVIVAL AFTER ALLOGENEIC TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA IN ADULTS IN DENMARK FROM 2000 TO 2020: A POPULATION-BASED COHORT STUDY | Lars Klingen Gjćrde | ![]() |
![]() |
|||
539-P | PROGNOSTIC RELEVANCE OF MINIMAL RESIDUAL DISEASE IN THERAPY RELATED AND SECONDARY ACUTE MYELOID LEUKEMIA RECEIVING CPX-351 OR FLUDARABINE-BASED INDUCTION. | Fabio Guolo | ![]() |
![]() |
|||
540-P | PEVONEDISTAT, AZACITIDINE AND VENETOCLAX FOR PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA– A PHASE I STUDY | Guru Subramanian Guru Murthy | ![]() |
![]() |
|||
545-P | CHARACTERISTICS AND OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND TRISOMY 19 | Sabine Kayser | ![]() |
![]() |
|||
546-P | EFFECTS OF CHEMOTHERAPY DOSE REDUCTIONS IN OVERWEIGHT AND OBESE PATIENTS WITH ACUTE MYELOID LEUKEMIA – A DANISH NATIONWIDE COHORT STUDY | Daniel Kristensen | ![]() |
![]() |
|||
556-P | CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB AZACITIDINE OR PLACEBO AZACITIDINE | Steve Waye | ![]() |
![]() |
|||
557-P | HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA | Hartmut Dohner | ![]() |
![]() |
|||
558-P | GERMAN AMLCG-SURVIVORSHIP STUDY – SOMATIC LONG-TERM CONSEQUENCE OF AML AND ITS THERAPY: FROM HEART TO KIDNEY. | Anna Sophia Moret | ![]() |
![]() |
|||
564-P | FINAL RESULTS OF THE QOLESS AZA-AMLE RANDOMIZED TRIAL TO EVALUATE THE EFFICACY OF 5-AZA FOR POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS | Esther Natalie Oliva | ![]() |
![]() |
|||
565-P | IMPROVED OUTCOME OF PATIENS WITH ACUTE MYELOID LEUKEMIA HARBORING FLT3 MUTATION IN THE ERA OF TARGETED THERAPY | Guadalupe Ońate | ![]() |
![]() |
|||
566-P | IMPACT OF FRONTLINE INDUCTION APPROACH ON POST-STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) | Faustine Ong | ![]() |
![]() |
|||
574-P | CPX-351 COMBINED WITH HEMATOPOIETIC CELL TRANSPLANTATION WITH REGULATORY AND CONVENTIONAL T CELL IMMUNOTHERAPY FOR HIGH-RISK ACUTE MYELOID LEUKEMIA | Sofia Sciabolacci | ![]() |
![]() |
|||
578-P | GILTERITINIB FOR RELAPSED/REFRACTORY FLT3 MUTATED ACUTE MYELOID LEUKEMIA A REAL-WORLD, MULTI-CENTER, MATCHED ANALYSIS | Eitan Kugler | ![]() |
![]() |
|||
585-P | VENETOCLAX IN COMBINATION WITH INTENSIVE TREATMENT PROTOCOLS FOR PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA – A MULTICENTER REAL-WORLD ANALYSIS | Ofir Wolach | ![]() |
![]() |
|||
587-P | COVALENT-101: A PHASE 1 STUDY OF BMF-219, A NOVEL ORAL IRREVERSIBLE MENIN INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIA, DIFFUSE LARGE B-CELL LYMPHOMA, AND MULTIPLE MYELOMA | Farhad Ravandi-Kashani | ![]() |
![]() |
|||
588-P | IMPROVED OUTCOME OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA BY ADDITION OF LIPOSOMAL ADRIAMYCIN TO CLAG CHEMOTHERAPY | Han Yao | ![]() |
![]() |
|||
589-P | AGE AND AGE-ADAPTED RISK FACTORS HIGHLY INFLUENCE SURVIVAL PROBABILITY IN AML PATIENTS – A RETROSPECTIVE ANALYSIS | Charlotte Zahner | ![]() |
![]() |
|||
592-P | GILTERITINIB IN COMBINATION WITH VENETOCLAX, LOW DOSE CYTARABINE AND ACTINOMYCIN D FOR FLT3 MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA | Andrius Žucenka | ![]() |
![]() |
|||
593-P | MULTIDIMENSIONAL ANALYSIS OF THE B CELL RECEPTOR OFFERS INSIGHT INTO THE ONTOGENETIC RELATIONSHIP OF MONOCLONAL B-CELL LYMPHOCYTOSIS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | Andreas Agathangelidis | ![]() |
![]() |
|||
595-P | DISCOVERY OF NOVEL CIRCULAR RNAS (CIRCRNAS) OF THE APOPTOSIS-RELATED BAX AND BCL2L12 GENES WITH A MULTIFACETED ROLE IN CHRONIC LYMPHOCYTIC LEUKEMIA, USING CUTTING-EDGE NANOPORE SEQUENCING TECHNOLOGY | Pinelopi Artemaki | ![]() |
![]() |
|||
596-P | CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE | Riccardo Bomben | ![]() |
![]() |
|||
599-P | RARE GERMLINE VARIANTS IN ATM INFLUENCE THE PATHOGENESIS OF CLL | Jennifer R. Brown | ![]() |
![]() |
|||
600-P | HIGH-DEPTH RNA-SEQUENCING IDENTIFIES CD8+ STAT3 MUTATED T-LGLL PATIENTS AS A DISTINCT BIOLOGICAL ENTITY WITHIN THE DISEASE HETEROGENEITY | Giulia Calabretto | ![]() |
![]() |
|||
604-P | CATALASE EXPRESSION IN LEUKEMIA CELLS IS CONTROLLED BY GENETIC AND EPIGENETIC MECHANISMS | Marilisa Galasso | ![]() |
![]() |
|||
605-P | T-CELL PROLYMPHOCYTIC LEUKEMIA: MOLECULAR CHARACTERIZATION OF A COHORT OF 18 PATIENTS AND EVALUATION OF BORTEZOMIB AS A POSSIBLE THERAPEUTIC STRATEGY | Vanessa Rebecca Gasparini | ![]() |
![]() |
|||
609-P | CLINICOBIOLOGICAL CHARACTERISTICS AND TREATMENT EFFICACY OF NOVEL AGENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH IGLV3-21R110 | Paul Hengeveld | ![]() |
![]() |
|||
612-P | CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)-DERIVED T-CELLS HAVE DISTURBED FATTY ACID METABOLISM, POSSIBLY CONTRIBUTING TO T-CELL DYSFUNCTION | Chaja F Jacobs | ![]() |
![]() |
|||
622-P | DOUBLE-HIT TRAF3 DELETION AND MUTATION IDENTIFIED BY HIGH-THROUGHPUT SEQUENCING DEFINE A NEW INDEPENDENT PROGNOSTIC FACTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA | Claudia Perez-Carretero | ![]() |
![]() |
|||
623-P | IBRUTINIB REGULATES MIR-181A/B VIA C-FOS IN CHRONIC LYMPHOCYTIC LEUKEMIA | Alice Ramassone | ![]() |
![]() |
|||
626-P | FUNCTIONAL SCREENING OF PI3K INHIBITORS STRATIFIES RESPONDERS TO IDELALISIB AND INDICATES DRUG CLASS ACTIVITY IN IDELALISIB-REFRACTORY CLL | Sigrid Skĺnland | ![]() |
![]() |
|||
631-P | A PCR-BASED ASSAY FOR IGLV3-21R110 SCREENING CONFIRMS ITS PROGNOSTIC VALUE IN AN INDEPENDENT COHORT OF 613 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA. | Charlotte Syrykh | ![]() |
![]() |
|||
633-P | ACTIVE CHROMATIN REGULATORY LANDSCAPE OF STEREOTYPED SUBSETS IN CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS A DISTINCTIVE SIGNATURE IN SUBSET #8 | Maria Tsagiopoulou | ![]() |
![]() |
|||
634-P | MHC-BASED LARGE-SCALE SCREENING FOR ANTI-TUMOR T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA REVEALS CD8+ T CELLS WITH SPECIFICITY AGAINST THE CLONOTYPIC B-CELL RECEPTOR IMMUNOGLOBULIN | Anna Vardi | ![]() |
![]() |
|||
636-P | REAL WORLD OUTCOME WITH IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA FROM THE GERMAN REALITY STUDY | Manfred Welslau | ![]() |
![]() |
|||
637-P | FRONTLINE THERAPY CLL WITHOUT 17P DEL/P53 ABERRATIONS: SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS | Marco Rossi | ![]() |
![]() |
|||
639-P | OUTCOMES FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA PREVIOUSLY TREATED WITH A COVALENT BTK AND BCL2 INHIBITOR IN THE UNITED STATES: A REAL-WORLD DATABASE STUDY | Anthony R. Mato | ![]() |
![]() |
|||
640-P | PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN COMBINATION WITH VENETOCLAX±RITUXIMAB IN RELAPSED/REFRACTORY CLL: RESULTS FROM THE BRUIN PHASE 1B STUDY | Lindsey E. Roeker | ![]() |
![]() |
|||
642-P | IMPACT OF TYPE 2 DIABETES ON SURVIVAL AND TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | Emelie Curovic Rotbain | ![]() |
![]() |
|||
644-P | THE LIFE EXPECTANCY OF PATIENTS WITH HAIRY CELL LEUKEMIA VERGES UPON THE LIFE EXPECTANCY OF THE GENERAL POPULATION: A POPULATION-BASED STUDY IN THE NETHERLANDS | Avinash Dinmohamed | ![]() |
![]() |
|||
651-P | VENETOCLAX-BASED TREATMENT OF PATIENTS WITH RICHTER SYNDROME: OUTCOMES FROM A MULTICENTER RETROSPECTIVE STUDY | Paul Hampel | ![]() |
![]() |
|||
652-P | MEASURING MINIMAL RESIDUAL DISEASE BEYOND 10-4 THROUGH IGHV LEADER-BASED NEXT GENERATION SEQUENCING IMPROVES PROGNOSTIC STRATIFICATION IN CHRONIC LYMPHOCYTIC LEUKEMIA | Paul Hengeveld | ![]() |
![]() |
|||
653-P | OUTCOMES FOLLOWING TREATMENT WITH A COVALENT BTK AND BCL2 INHIBITOR AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): A REAL-WORLD STUDY OF A LARGE U.S. DATABASE | Toby A Eyre | ![]() |
![]() |
|||
656-P | INCIDENT VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH MONOCLONAL B-CELL LYMPHOCYTOSIS (MBL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) – A POPULATION-BASED STUDY | Amber Koehler | ![]() |
![]() |
|||
659-P | IBRUTINIB IN OVER-EIGHTIES PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER ITALIAN COHORT | Veronica Mattiello | ![]() |
![]() |
|||
669-P | FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 3-YEAR FOLLOW-UP FROM THE PHASE 2 CAPTIVATE STUDY FD COHORT | Carol Moreno | ![]() |
![]() |
|||
670-P | ABSENCE OF BTK, BCL2, AND PLCG2 MUTATIONS IN RELAPSING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER FIRST-LINE TREATMENT WITH FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) | Lisa J. Croner | ![]() |
![]() |
|||
671-P | TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL TREATED WITH TARGETED AGENTS IN REAL-WORLD SETTINGS | Anthony R. Mato | ![]() |
![]() |
|||
673-P | DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX. | Andy Rawstron | ![]() |
![]() |
|||
674-P | UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | Christine Ryan | ![]() |
![]() |
|||
675-P | TREATMENT OF HYPERTENSION IN PATIENTS RECEIVING BTK INHIBITORS: A MULTICENTER RETROSPECTIVE STUDY | Mazyar Shadman | ![]() |
![]() |
|||
677-P | CLINICAL EFFICACY AND TOLERABILITY OF VENETOCLAX PLUS RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA – REAL WORLD ANALYSIS OF POLISH ADULT LEUKEMIA STUDY GROUP | Anita Sobon | ![]() |
![]() |
|||
680-P | SARCOPENIA EVALUATED BY CT SCAN IS ASSOCIATED WITH SHORTER SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH TARGETED THERAPIES. A PROSPECTIVE STUDY. | Andrea Visentin | ![]() |
![]() |
|||
683-P | A FIRST-IN-HUMAN PHASE 1 STUDY OF ORAL LOXO-338, A SELECTIVE BCL2 INHIBITOR, IN PATIENTS WITH ADVANCED HEMATOLOGIC MALIGNANCIES (TRIAL IN PROGRESS) | Wojciech Jurczak | ![]() |
![]() |
|||
684-P | PHASE 1 STUDY OF LP-108, A SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA | Wei Xu | ![]() |
![]() |
|||
688-P | VIRTUAL SCREENING PROTOCOL TO IDENTIFY TYROSINE KINASE INHIBITORS WITH A POTENTIAL TO INTERACT WITH P-GLYCOPROTEIN AND TO ACT AS MDR CHEMOSENSITIZERS: A VALIDATION STUDY | Elina Beleva | ![]() |
![]() |
|||
691-P | MODELLING OF IMMUNE RESPONSE IN CHRONIC MYELOID LEUKEMIA PATIENTS SUGGESTS POTENTIAL FOR TREATMENT REDUCTION PRIOR TO CESSATION | Ingmar Glauche | ![]() |
![]() |
|||
694-P | INVESTIGATING THE ROLE OF CELL ADHESION MOLECULES IN TUNNELING NANOTUBES FORMATION IN CHRONIC MYELOID LEUKEMIA MICROENVIRONMENT | Laura Turos-Korgul | ![]() |
![]() |
|||
696-P | SUBTHERAPEUTIC TKI DOSES FOR THE MAINTENANCE OF CML PATIENTS WITH INTOLERANCE OR REFUSAL TO DISCONTINUE: A SINGLE CENTER FEASIBILITY STUDY. | Asuncion Borrero | ![]() |
![]() |
|||
697-P | PONATINIB IN A REAL-LIFE SETTING: A RETROSPECTIVE ANALYSIS FROM THE MONITORING REGISTRIES OF THE ITALIAN MEDICINES AGENCY (AIFA) | Massimo Breccia | ![]() |
![]() |
|||
699-P | REAL-LIFE OUTCOMES OF PONATINIB TREATMENT IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) OR PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL): 5-YEAR-DATA FROM A BELGIAN REGISTRY | Timothy Devos | ![]() |
![]() |
|||
707-P | DOSE MODIFICATION DYNAMICS OF PONATINIB IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) FROM THE PACE AND OPTIC TRIALS | Jane Apperley | ![]() |
![]() |
|||
708-P | CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY. | Fatima Khadadah | ![]() |
![]() |
|||
709-P | CLINICAL OUTCOME OF ASCIMINIB TREATMENT IN A REAL-WORLD MULTI-RESISTANT CML PATIENT POPULATION. | Camille C.B. Kockerols | ![]() |
![]() |
|||
711-P | KINETICS OF CITED2 GENE EXPRESSION IN CHRONIC MYELOID LEUKEMIA PATIENTS | Basma Atef | ![]() |
![]() |
|||
716-P | OUTCOMES AND PATTERNS OF TREATMENT IN CHRONIC MYELOID LEUKEMIA, A GLOBAL PERSPECTIVE BASED ON A REAL-WORLD DATA GLOBAL NETWORK | Alejandro Sanz | ![]() |
![]() |
|||
717-P | BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL | Jorge E Cortes | ![]() |
![]() |
|||
721-P | PREDICTIVE SCORING SYSTEMS FOR MOLECULAR RESPONSES IN PERSONS WITH CHRONIC MYELOID LEUKEMIA RECEIVING INITIAL IMATINIB THERAPY | Xiaoshuai Zhang | ![]() |
![]() |
|||
723-P | LOSS OF THE NK MOTIF AND ANKYRIN REPEAT DOMAIN 1 (KANK1) LEADS TO LYMPHOID COMPARTMENT DYSREGUATION IN MICE | Marwa Almosailleakh | ![]() |
![]() |
|||
724-P | THE BONE MARROW MESENCHYMAL CELL-DERIVED EXTRACELLULAR MATRIX IS SIGNIFICANTLY ALTERED IN PATIENTS WITH MELODYSPLASTIC SYNDROMES | Amanpreet Bains | ![]() |
![]() |
|||
725-P | METABOLIC PROPERTIES OF MESENCHYMAL STROMAL CELLS IN MYELODYSPLASTIC SYNDROMES | Manja Wobus | ![]() |
![]() |
|||
726-P | MYELOID-DERIVED SUPPRESSOR CELLS AS POTENTIAL TARGETS FOR IMMUNE THERAPY IN CCUS AND LOW RISK MDS | Sofia Bentivegna | ![]() |
![]() |
|||
728-P | GENE EXPRESSION PROFILE REVELS T-LYMPHOCYTES ACTIVATION THROUGH CELL CYCLE PROGRESSION AND MITOCHONDRIAL METABOLISM REGULATION IN MYELODYSPLASTIC SYNDROMES WITH DEL(5Q) AFTER LENALIDOMIDE TREATMENT | Mónica Del Rey | ![]() |
![]() |
|||
729-P | DEREGULATION OF NONCODING RNAS DERIVED FROM KDM GENES IS ASSOCIATED WITH AZACITIDINE RESPONSE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA | Michaela Dostalova Merkerova | ![]() |
![]() |
|||
731-P | INTERPLAY BETWEEN INFLAMMATION AND EPIGENETICS IN TUMOR REPROGRAMMING OF MESENCHYMAL STROMAL CELLS (MSCS) IN MYELODYSPLASTIC SYNDROMES (MDS) | Cesarina Giallongo | ![]() |
![]() |
|||
732-P | TH17/TREG IMBALANCE IN LOW RISK MDS PATIENTS | Sofia Grille | ![]() |
![]() |
|||
733-P | DHX9 HELICASE DYSFUNCTION CONTRIBUTES TO DISEASE PROGRESSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES | Feng Xu | ![]() |
![]() |
|||
734-P | DOWN-REGULATION OF RING1 AND YY1 BINDING (RYBP) LEADS TO EPIGENETIC OVEREXPRESSION OF ANTI-APOPTOTIC PROTEIN BCL2 IN MYELODYSPLASTIC SYNDROMES | Feng Xu | ![]() |
![]() |
|||
736-P | BCOR MUTATION REGULATES MYELODYSPLASTIC SYNDROMES PROGRESSION THROUGH REPRESSING AUTOPHAGY FLUX MEDIATED BY HDAC6 ACTIVATION | Wu Lingyun | ![]() |
![]() |
|||
739-P | THE EPI-GENOMIC LANDSCAPE OF MONOSOMY 7 IN ADULT MDS/AML | Anair Graciela Lema Fernandez | ![]() |
![]() |
|||
742-P | TRANSCRIPTOMIC ANALYSIS OF ISOLATED CD4+ AND CD8+ T CELLS REVEALS DIFFERENCES IN TCR REPERTOIRE IN PATIENTS WITH HIGH RISK MDS COMPARED TO AML. | Ioannis Mitroulis | ![]() |
![]() |
|||
751-P | CHARACTERIZING CIRCULAR RNA EXPRESSION IN MYELODYSPLASTIC SYNDROME | Eileen Wedge | ![]() |
![]() |
|||
752-P | TARGETING S100A9 IN THE MYELODYSPLASTIC INFLAMMATORY BONE MARROW MICROENVIRONMENT BY TASQUINIMOD IMPROVES THE SUPPORTIVE FUNCTION OF MESENCHYMAL STROMAL CELLS | Manja Wobus | ![]() |
![]() |
|||
755-P | HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML | Luis E. Aguirre | ![]() |
![]() |
|||
758-P | INHIBITION OF ATR WITH CERALASERTIB (AZD6738) FOR THE TREATMENT OF PROGRESSIVE OR RELAPSED MYELODYSPLASTIC SYNDROMES AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A PHASE IB/II STUDY | Andrew Brunner | ![]() |
![]() |
|||
761-P | MONOCYTOSIS IN PRIMARY CARE AND HEMATOLOGICAL MALIGNANCIES | Mathilde Christensen | ![]() |
![]() |
|||
762-P | NONLINIEAR IMPACT OF CLINICAL FEATURES ON THE SURVIVAL OUTCOME OF MYELODYSPLASTIC SYNDROMES PATIENTS | Faezeh Darbaniyan | ![]() |
![]() |
|||
764-P | RESPONSE AND SURVIVAL OUTCOMES WITH HYPOMETHYLATING AGENTS IN AN ARGENTINEAN COHORT OF 113 PATIENTS WITH CHRONIC MYELOMONOCITIC LEUKEMIA | Jacqueline Gonzalez | ![]() |
![]() |
|||
766-P | CLINICAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED ANALYSIS | Amer M. Zeidan | ![]() |
![]() |
|||
771-P | PROGNOSTIC CHARACTERISTICS OF PATIENTS WITH MDS WITH ABERRATIONS OF CHROMOSOME 5. DATA FROM THE DÜSSELDORF MDS REGISTRY | Joana Kostova | ![]() |
![]() |
|||
772-P | PROGNOSTIC IMPACT OF DISEASE-RELATED RISK FACTORS AND TREATMENT APPROACHES IN PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROMES (MDS) | Claudia Lesch | ![]() |
![]() |
|||
777-P | RUNX1 VARIANTS WITH HIGH VARIANT ALLELE FREQUENCY IN MYELOID NEOPLASMS. GERMLINE OR NOT? | Nikolaj Juul Nitschke | ![]() |
![]() |
|||
787-P | SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM | Amer M. Zeidan | ![]() |
![]() |
|||
792-P | CRISPR/CAS9-BASED MODEL OF HETEROZYGOUS CXCR4 WT/R334X MUTATION TO STUDY CELLULAR PHENOTYPES IN WHIM SYNDROME | Katarina Zmajkovicova | ![]() |
![]() |
|||
793-P | SCREENING OF NATURALLY OCCURRING CXCR4 VARIANTS FOR IDENTIFICATION OF NOVEL PATHOGENIC MUTATIONS FOR WHIM SYNDROME | Sumit Pawar | ![]() |
![]() |
|||
797-P | METABOLIC PROFILING IN ERCC6L2 AND SHWACHMAN DIAMOND SYNDROME | Ilse Kaaja | ![]() |
![]() |
|||
803-P | TELOMERE SHORTENING IN BONE MARROW MESENCHYMAL STEM CELLS OF ACQUIRED APLASTIC ANEMIA PATIENTS ASSOCIATE WITH ALTERED EXPRESSION OF GENES INVOLVED IN TELOMERE MAINTENANCE, DNA DAMAGE, AND SENESCENCE | Jyotika Srivastava | ![]() |
![]() |
|||
806-P | IMPACT OF MARROW HEMOPHAGOCYTOSIS IN DIAGNOSTIC DEFINITION AND PROGNOSTIC SIGNIFICANCE IN ADULT POPULATION | Cátia Almeida | ![]() |
![]() |
|||
808-P | CONGENITAL NEUTROPENIA PREVALENCE AMONG POLISH CHILDREN – SUMMARY OF A NATIONWIDE GENETIC SCREENING CAMPAIGN | Katarzyna Babol-Pokora | ![]() |
![]() |
|||
817-P | SYNDROMES PREDISPOSING TO LEUKEMIA ARE A MAJOR CAUSE OF INHERITED CYTOPENIAS IN CHILDREN | Oded Gilad | ![]() |
![]() |
|||
819-P | TRANSPLANT, TREATMENT AND TRANSFUSION FREE (TTT-FREE) SURVIVAL AS RELEVANT CLINICAL ENDPOINT AFTER IMMUNOSUPPRESSIVE TREATMENT FOR ACQUIRED APLASTIC ANEMIA IN ADULTS | Cjm Halkes | ![]() |
![]() |
|||
825-P | FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAVE TO C5 INHIBITORS | Jordan Messer | ![]() |
![]() |
|||
826-P | FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS | Jordan Messer | ![]() |
![]() |
|||
832-P | CLINICAL OUTCOMES AND IMMUNE RESPONSES TO SARS-COV-2 VACCINATION IN PATIENTS WITH SEVERE APLASTIC ANEMIA | Roma Rajput | ![]() |
![]() |
|||
835-P | GENETIC BACKGROUND AND CLINICAL CHARACTERISTICS OF CONGENITAL NEUTROPENIAS IN ISRAEL | Orna Steinberg-Shemer | ![]() |
![]() |
|||
841-P | EXTRACELLULAR VESICLE PROTEINS AS BIOMARKER OF OUTCOME IN MULTIPLE MYELOMA - A REAL-WORLD STUDY | Emilie Arnault Carneiro | ![]() |
![]() |
|||
842-P | NOVEL MULTIFUNCTIONAL TETRAVALENT CD38 NKP46 FLEX-NK ENGAGERS ACTIVELY TARGET AND KILL MULTIPLE MYELOMA CELLS | Antonio Arulanandam | ![]() |
![]() |
|||
845-P | IDENTIFICATION OF MULTIPLE MYELOMA BIOMARKERS VIA LIQUID BIOPSY BASED ON CELL-FREE DNA USING A CAPTURE-HYBRIDIZATION PANEL | Natalia Buenache Cuenda | ![]() |
![]() |
|||
846-P | EXPRESSION SIGNATURE OF TP53 BIALLELIC INACTIVATION IDENTIFIES A GROUP OF MULTIPLE MYELOMA PATIENTS WITHOUT THIS GENETIC CONDITION BUT WITH DISMAL OUTCOME. | Cristina De Ramón | ![]() |
![]() |
|||
848-P | TINOSTAMUSTINE (EDO-S101), AN ALKYLATOR AND HISTONE DEACETYLASE INHIBITOR, ENHANCES THE EFFICACY OF DARATUMUMAB IN PRECLINICAL MODELS OF MULTIPLE MYELOMA | Andrea Diaz-Tejedor | ![]() |
![]() |
|||
849-P | DEPLETION OF DIS3 IN MULTIPLE MYELOMA LEADS TO PERTURBATION IN RNA METABOLISM, CELL CYCLE PROGRESSION AND MITOTIC CHECKPOINT. | Vanessa Favasuli | ![]() |
![]() |
|||
851-P | TARGETING GENE DEPENDENCIES IN MYC OVEREXPRESSING MULTIPLE MYELOMA | Lama Hasan Bou Issa | ![]() |
![]() |
|||
855-P | SYNERGISTIC EFFICACY OF COMBINED SUMOYLATION AND PROTEASOME INHIBITION IN MULTIPLE MYELOMA | Ulrich Keller | ![]() |
![]() |
|||
857-P | BORTEZOMIB- AND CARFILZOMIB-RESISTANT MYELOMA CELLS SHOW INCREASED ACTIVITY OF ALL THREE ARMS OF UNFOLDED PROTEIN RESPONSE AND ENRICHMENT OF SIRTUIN SIGNALING PATHWAY | Tadeusz Kubicki | ![]() |
![]() |
|||
858-P | EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR T-CELL CYTOTOXICITY | Laura Martinez-Verbo | ![]() |
![]() |
|||
859-P | ANTI-CD38 NANOBODY JK36 ALLOWS RELIABLE MRD DETECTION IN DARATUMUMAB TREATED MULTIPLE MYELOMA PATIENTS | Elena Meseguer Martinez | ![]() |
![]() |
|||
861-P | SIALOFUCOSYLATED STRUCTURES ENABLE PLATELET BINDING TO MYELOMA CELLS CONFERRING PROTECTION FROM NK-MEDIATED CYTOTOXICITY | Alessandro Natoni | ![]() |
![]() |
|||
863-P | GENERATION OF A FIRST-IN-CLASS INHIBITOR FOR THE MASTER ONCOREGULATOR HNRNP K IN MULTIPLE MYELOMA | Álvaro Otero Sobrino | ![]() |
![]() |
|||
864-P | CTPS1 IS A NOVEL THERAPEUTIC TARGET IN MYELOMA - SELECTIVE SMALL MOLECULE INHIBITION DELIVERS SINGLE AGENT ACTIVITY AND SYNERGISES WITH ATR INHIBITION | Christina Pfeiffer | ![]() |
![]() |
|||
869-P | PRODUCTION BY GUT MICROBIOTA AS PROGNOSTIC BIOMARKER IN MM | Alba Rodríguez-García | ![]() |
![]() |
|||
872-P | DEL(1P32) REMAINS A POWERFUL PROGNOSTIC FACTOR IN A LARGE COHORT OF NDMM PATIENTS: AN UPDATE | Anaďs Schavgoulidze | ![]() |
![]() |
|||
873-P | CARFILZOMIB RESISTANCE IS ASSOCIATED WITH SIGNIFICANT DEREGULATION OF THE BH3 FAMILY PROTEINS | Anja Schneller | ![]() |
![]() |
|||
875-P | ACTIVATION OF LNCRNA NEAT1 LEADS TO SURVIVAL ADVANTAGE OF MULTIPLE MYELOMA CELLS BY SUPPORTING A REGULATORY LOOP WITH DNA REPAIR PROTEINS: RATIONAL BASES FOR NEAT1 THERAPEUTIC TARGETING IN THE DISEASE | Elisa Taiana | ![]() |
![]() |
|||
879-P | EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA | Stefanie Huhn | ![]() |
![]() |
|||
888-P | REPLACING STEROIDS IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: THE PHASE 2 ISATUXIMAB-BORTEZOMIB-LENALIDOMIDE-DEXAMETHASONE REST STUDY | Frida Bugge Askeland | ![]() |
![]() |
|||
889-P | WILL OUTCOME IMPROVE BY TREATING MULTIPLE MYELOMA PATIENTS AT MRD RELAPSE? THE REMNANT STUDY (RELAPSE FROM MRD NEGATIVITY AS INDICATION FOR TREATMENT) | Frida Bugge Askeland | ![]() |
![]() |
|||
891-P | IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01 | Xavier Leleu | ![]() |
![]() |
|||
894-P | A PHASE II TRIAL TO EVALUATE THE EFFICACY OF DARATUMUMAB WITH DCEP IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER BORTEZOMIB BASED TREATMENT | Ja Min Byun | ![]() |
![]() |
|||
897-P | UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA | Andrew Dalovisio | ![]() |
![]() |
|||
900-P | SALVAGE AUTOLOGOUS STEM CELL TRANSPLANT IN RELAPSED MULTIPLE MYELOMA: A SINGLE CENTRE EXPERIENCE | Sara Duarte | ![]() |
![]() |
|||
902-P | RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS. A MULTICENTER RETROSPECTIVE ANALYSIS OF ELIGIBILITY CRITERIA FOR CAR-T CELL THERAPY | Francesca Fazio | ![]() |
![]() |
|||
905-P | IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13 | Kaz Groen | ![]() |
![]() |
|||
906-P | IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY | Kaz Groen | ![]() |
![]() |
|||
907-P | CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY | Hang Quach | ![]() |
![]() |
|||
911-P | SYMPTOM BURDEN AND ITS IMPACT ON DAILY LIFE AMONG PATIENTS WITH IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE (IMCD) – FINDINGS FROM AN INTERNATIONAL IMCD PATIENT SURVEY | Sudipto Mukherjee | ![]() |
![]() |
|||
916-P | COEXISTENCE OF =2 HIGH-RISK MOLECULAR ABNORMALITIES SUPERVENES THE PROGNOSTIC VALUE OF THE REVISED INTERNATIONAL STAGING SYSTEM FOR MYELOMA: REAL-WORLD DATA ANALYSIS FROM THE GREEK MYELOMA STUDY GROUP | Eirini Katodritou | ![]() |
![]() |
|||
917-P | HOW COMORBID ARE OUR MYELOMA PATIENTS AND HOW MANY MAKE IT TO THE SECOND-LINE TREATMENT: REAL-WORLD DATA OF 251 MYELOMA PATIENTS TREATED IN THE HEMATOLOGICAL NETWORK OF THE OEGK | Felix Keil | ![]() |
![]() |
|||
918-P | HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAFODOTIN IN RELAPSED SYSTEMIC AL AMYLOIDOSIS | Jahanzaib Khwaja | ![]() |
![]() |
|||
923-P | TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATIONS STILL BENEFIT FOR MYELOMA PATIENTS: A POOLING META-ANALYSIS | Cho-Hao Lee | ![]() |
![]() |
|||
926-P | DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DANTE TRIAL | Lisa Leypoldt | ![]() |
![]() |
|||
928-P | REAL-LIFE ANALYSIS OF THE MULTIPLE MYELOMA PATIENT´S SURVIVAL IN A LARGE COHORT OF PATIENTS | Nieves Lopez-Muńoz | ![]() |
![]() |
|||
929-P | IXAZOMIB AND DARATUMUMAB WITHOUT DEXAMETHASONE (I-DARA) IN ELDERLY FRAIL RELAPSING MYELOMA (RRMM) PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018-02 OF THE INTERGROUPE FRANCOPHONE DU MYELOME (IFM). | Margaret Macro | ![]() |
![]() |
|||
931-P | PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY OF GAUCHER DISEASE PREVALENCE IN PATIENTS AFFECTED BY MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE | Gaetano Giuffrida | ![]() |
![]() |
|||
932-P | ON-DEMAND PLERIXAFOR WITH CYCLOPHOSPHAMIDE AND G-CSF FOR HEMATOPOIETIC STEM-CELL MOBILIZATION IN MULTIPLE MYELOMA PATIENTS: FINAL RESULTS OF THE MOZOBL06877 STUDY | Roberto Mina | ![]() |
![]() |
|||
933-P | DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAPSE AFTER INITIAL THERAPY | Andrew Spencer | ![]() |
![]() |
|||
934-P | DARATUMUMAB + LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST HOC ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVITY FROM GRIFFIN | Cesar Rodriguez | ![]() |
![]() |
|||
936-P | TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF THE PHASE 3 MAIA STUDY | Thierry Facon | ![]() |
![]() |
|||
938-P | CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE CONSOLIDATION IN MYELOMA PATIENTS WITH A POSITIVE FDG PET/CT AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION: A PHASE II STUDY (CONPET) | Jakob Nordberg Nřrgaard | ![]() |
![]() |
|||
944-P | A PHASE I STUDY OF C-CAR088, A NOVEL HUMANIZED ANTI-BCMA CAR T CELL THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA | Xiaoyan Qu | ![]() |
![]() |
|||
945-P | SUBCUTANEOUS ISATUXIMAB ADMINISTRATION BY AN ON-BODY DELIVERY SYSTEM IN COMBINATION WITH POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: INTERIM PHASE 1B STUDY RESULTS | Hang Quach | ![]() |
![]() |
|||
948-P | INCIDENCE AND CLINICAL OUTCOME OF SARS-COV-2 INFECTION AFTER VACCINATION IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE (MGUS) | Nicola Sgherza | ![]() |
![]() |
|||
950-P | COMBINED PROTEASOME AND AUTOPHAGY INHIBITION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA – A PHASE I TRIAL OF HYDROXYCHLOROQUINE, CARFILZOMIB AND DEXAMETHASONE | Tobias S. Slřrdahl | ![]() |
![]() |
|||
952-P | THE ROLE OF AGE IN THE LONG-TERM TREATMENT OF MULTIPLE MYELOMA - A LONGITUDINAL ANALYSIS OF REGULAR CARE DATA | H Tilman Steinmetz | ![]() |
![]() |
|||
963-P | EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS OF THE PREAMBLE COHORT | David Kuter | ![]() |
![]() |
|||
966-P | DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE | Iuliana Vaxman | ![]() |
![]() |
|||
968-P | ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202 | Peter Voorhees | ![]() |
![]() |
|||
970-P | SAFETY AND EFFICACY OF BCMA-CAR-T IMMUNE CELLS DERIVED FROM CORD BLOOD IN THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA | Ying Gao | ![]() |
![]() |
|||
973-P | REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY, SPAIN, AND ITALY | Katja Weisel | ![]() |
![]() |
|||
979-P | EXOSOMES IN POLYCYTHEMIA VERA: "MINI PLATELETS" WITH THROMBOGENIC POTENTIAL | Adi Abulafia | ![]() |
![]() |
|||
980-P | JAK2V617F-DEPENDENT DOWN REGULATION OF SHP1 EXPRESSION PARTICIPATES IN THE SELECTION OF MPN CELLS IN THE PRESENCE OF TGF? | Celine Aoun | ![]() |
![]() |
|||
982-P | MYELOID-DERIVED SUPPRESSOR CELLS: CHARACTERIZATION IN PERIPHERAL BLOOD AND SPLEEN TISSUE OF PATIENTS WITH MYELOFIBROSIS | Rita Campanelli | ![]() |
![]() |
|||
983-P | SINGLE CELL ANALYSIS ALLOWS THE EARLY DETECTION OF LEUKEMIC CLONES IN MPN PATIENTS | Chiara Carretta | ![]() |
![]() |
|||
984-P | MUTATIONAL PATTERNS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS (MPN) | Ilaria Carola Casetti | ![]() |
![]() |
|||
985-P | THE ALLELIC RATIO OF DRIVER AND ASXL1 MUTATIONS IS PROGNOSTICALLY RELEVANT IN PMF | Giacomo Coltro | ![]() |
![]() |
|||
986-P | CYTOGENETIC DIAGNOSIS WITH NEXT-GENERATION CYTOGENETICS BY OPTICAL GENOME MAPPING IN PATIENTS WITH MYELOFIBROSIS. | Álvaro Díaz González | ![]() |
![]() |
|||
987-P | A DIFFERENT BALANCE IN OXIDATIVE STRESS RESPONSE IN CALR AND JAK2 MUTATED MYELOFIBROSIS PATIENTS CORRELATES WITH CLINICAL OUTCOME | Elena Genovese | ![]() |
![]() |
|||
988-P | LACTATE RESHAPES TUMOR MICROENVIRONMENT AND METABOLIC PROFILE IN MYELOFIBROSIS | Sebastiano Giallongo | ![]() |
![]() |
|||
990-P | T CELL RESPONSE AND OMICRON VARIANT NEUTRALISATION FOLLOWING VACCINATION AGAINST SARS-COV-2 IN PATIENTS WITH CHRONIC MYELOID DISORDERS | Patrick Harrington | ![]() |
![]() |
|||
991-P | IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB | Patrick Harrington | ![]() |
![]() |
|||
992-P | OUTCOMES OF GLOBAL COAGULATION ASSAYS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH RESPECT TO THEIR CLINICAL AND GENETIC DETERMINANTS OF CLONAL EVOLUTION | Alessandro Lucchesi | ![]() |
![]() |
|||
993-P | SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS | Manuela Mancini | ![]() |
![]() |
|||
995-P | MYELOID NEOPLASMS-ASSOCIATED GENE VARIANTS IN 639 PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT | Barbara Mora | ![]() |
![]() |
|||
1002-P | ANTI-FIBROTIC ACTIVITY OF BMP2 IN BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS OF MYELOPROLIFERATIVE NEOPLASMS | Tijana Suboticki | ![]() |
![]() |
|||
1003-P | PERIPHERAL BLOOD CYTOTOXIC T CELLS SHOW EARLY EXHAUSTED FEATURES IN MYELOFIBROSIS PATIENTS | Lara Tavernari | ![]() |
![]() |
|||
1005-P | A PHASE 1, OPEN-LABEL, DOSE-ESCALATION STUDY OF SELINEXOR PLUS RUXOLITINIB IN PATIENTS WITH TREATMENT-NAĎVE MYELOFIBROSIS | Haris Ali | ![]() |
![]() |
|||
1010-P | RUXOLITINIB IN MYELODEPLETIVE MYELOFIBROSIS: RESPONSE, TOXICITY, AND OUTCOME | Francesca Palandri | ![]() |
![]() |
|||
1011-P | PREDICTORS OF COVID-19 DISEASE AND SURVIVAL TO COVID-19 IN MPN PATIENTS TREATED WITH RUXOLITINIB | Francesca Palandri | ![]() |
![]() |
|||
1016-P | POLYCYTHEMIA VERA AND IMMUNE THROMBOGENESIS | Rossella Cacciola | ![]() |
![]() |
|||
1021-P | ERYTHROCYTOSIS, THROMBOCYTOSIS AND RATE OF RECURRENT THROMBOEMBOLIC EVENT - A POPULATION BASED COHORT STUDY | Anneli Enblom-Larsson | ![]() |
![]() |
|||
1025-P | RUXOLITINIB-ASSOCIATED CRYPTOCOCCOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS | Mihnea-Alexandru Gaman | ![]() |
![]() |
|||
1028-P | PTG-300 (RUSFERTIDE) TREATMENT INTERRUPTION REVERSES HEMATOLOGICAL GAINS AND RESTORES THERAPEUTIC BENEFIT ON REINITIATION IN SUBJECTS WITH POLYCYTHEMIA VERA | Andrew Kuykendall | ![]() |
![]() |
|||
1032-P | REAL-LIFE VALIDATION OF MIPSS70: A RETROSPECTIVE MULTICENTER AND NGS ANALYSIS FROM THE GEMFIN DATABASE | Alberto Hernández-Sánchez | ![]() |
![]() |
|||
1033-P | A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET) | Alycia Shilton | ![]() |
![]() |
|||
1037-P | DOES EARLY INTERVENTION IN MYELOFIBROSIS IMPACT OUTCOMES? A POOLED ANALYSIS OF THE COMFORT I AND II STUDIES | Claire Harrison | ![]() |
![]() |
|||
1043-P | OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER | Lucia Masarova | ![]() |
![]() |
|||
1045-P | IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS? | Erika Morsia | ![]() |
![]() |
|||
1046-P | SEVERE COMPLICATIONS IN JAK2 V617F POSITIVE PEDIATRIC PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS | Wolfgang Novak | ![]() |
![]() |
|||
1048-P | MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR | Faye Feller | ![]() |
![]() |
|||
1051-P | A PHASE 2 STUDY OF IMG-7289 (BOMEDEMSTAT) IN PATIENTS WITH ADVANCED MYELOFIBROSIS | Alycia Shilton | ![]() |
![]() |
|||
1052-P | IMPACT OF SF3B1 MUTATION IN MYELOFIBROSIS | Jayastu Senapati | ![]() |
![]() |
|||
1055-P | CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG-0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA | Frank Stegelmann | ![]() |
![]() |
|||
1057-P | REAL-WORLD UTILIZATION OF FEDRATINIB FOR MYELOFIBROSIS FOLLOWING RUXOLITINIB FAILURE | Claire Harrison | ![]() |
![]() |
|||
1060-P | REAL-WORLD CLINICAL OUTCOMES AFTER 3 AND 6 MONTHS OF TREATMENT WITH FEDRATINIB FOLLOWING RUXOLITINIB FAILURE | John Mascarenhas | ![]() |
![]() |
|||
1062-P | A REAL-WORLD EVALUATION OF THE ASSOCIATION BETWEEN ELEVATED BLOOD COUNTS AND THROMBOTIC EVENTS IN POLYCYTHEMIA VERA: AN ANALYSIS OF DATA FROM THE REVEAL STUDY | Aaron T. Gerds | ![]() |
![]() |
|||
1063-P | EFFICACY AND SAFETY OF PARSACLISIB-RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY | Abdulraheem Yacoub | ![]() |
![]() |
|||
1064-P | CIRCULATING CYTOKINE LEVELS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS – PROFILE AND CLINICAL CORRELATIONS – A SINGLE CENTER STUDY | Gergana Tsvetkova | ![]() |
![]() |
|||
1065-P | CONGENITAL ERYTHROCYTOSIS DUE TO HETEROZYGOUS VARIANTS IN THE BISPHOSPHOGLYCERATE MUTASE GENE | Myrthe J. Van Dijk | ![]() |
![]() |
|||
1067-P | PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS | Ji-Nuo Wang | ![]() |
![]() |
|||
1074-P | PRIMARY REFRACTORY HODGKIN´S LYMPHOMA: A MOROCCAN MONOCENTRIC RETROSPECTIVE STUDY | Mounir Ababou | ![]() |
![]() |
|||
1075-P | EVALUATION OF CYTOKIN GENE POLYMOPHISMS AND GENE EXPRESSIONS IN PATIENTS WITH HODGKIN LYMPHOMA | Handan Haydaroglu Sahin | ![]() |
![]() |
|||
1076-P | A RETROSPECTIVE ANALYSIS ON OLD AND EMERGING PROGNOSTIC FACTORS IN CLASSICAL HODGKIN´S LYMPHOMA IN THE PET-GUIDED ERA | Alessandro Cellini | ![]() |
![]() |
|||
1078-P | PATIENTS WITH HODGKIN LYMPHOMA DEVELOP ADEQUATE HUMORAL SEROLOGICAL RESPONSE TO VACCINATION WITH TWO DOSES OF BNT162B2 AND THEIR IGG ANTIBODY LEVELS MARKEDLY INCREASE AFTER A THIRD VACCINE DOSE | Eldad Dann | ![]() |
![]() |
|||
1079-P | COMPARISON OF NOVEL SALVAGE REGIMENS AND TRADITIONAL SALVAGE CHEMOTHERAPY IN RELAPSED AND REFRACTORY CLASSIC HODGKIN LYMPHOMA | Daniel Ermann | ![]() |
![]() |
|||
1081-P | PET-ADAPTED THERAPY AFTER THREE CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA: LONG TERM FOLLOW UP OF THE GATLA LH-05 TRIAL | Astrid Pavlovsky | ![]() |
![]() |
|||
1082-P | SAFETY AND EFFICACY ANALYSIS IN OLDER PATIENTS TREATED WITHIN THE GATLA LH-05 PROTOCOL: PET-ADAPTED THERAPY AFTER 3 CYCLES OF ABVD FOR ALL STAGES OF HODGKIN LYMPHOMA | Nancy Lorena Fiad | ![]() |
![]() |
|||
1083-P | BRENTUXIMAB VEDOTIN, ETOPOSIDE, SOLUMEDROL, HIGH DOSE ARA-C & PLATINUM FOLLOWED BY HDT & APBSCT FOR REFRACTORY/RELAPSED HODGKIN LYMPHOMA PATIENTS: LONG-TERM RESULTS OF THE GELTAMO GROUP BRESHAP STUDY | Ramon Garcia-Sanz | ![]() |
![]() |
|||
1084-P | CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN´S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP). | Francesco Gaudio | ![]() |
![]() |
|||
1085-P | EVALUATION OF GONADAL FUNCTION IN YOUNG WOMEN DIAGNOSED WITH HODGKIN AND NON-HODGKIN LYMPHOMA | Angeliki N. Georgopoulou | ![]() |
![]() |
|||
1092-P | NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA (NLPHL): HISTOLOGYCAL AND CLINICAL REVIEW IN A SINGLE CENTRE. | Elena Rámila | ![]() |
![]() |
|||
1093-P | A NEW PROGNOSTIC MODEL FOR INDIVIDUAL OUTCOME PREDICTION IN ADVANCED-STAGE HODGKIN LYMPHOMA. | Rasmus Rask Kragh Jřrgensen | ![]() |
![]() |
|||
1094-P | CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER | Hadiyah Audil | ![]() |
![]() |
|||
1095-P | TREATMENT ATTRIBUTES FOR 3RD LINE FOLLICULAR LYMPHOMA TREATMENT DECISION-MAKING: PHYSICIAN PERSPECTIVES FROM A SURVEY ACROSS WESTERN EUROPE AND THE UNITED STATES | P. Connor Johnson | ![]() |
![]() |
|||
1096-P | TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA | Allison Bock | ![]() |
![]() |
|||
1098-P | OUTCOME OF FOLLICULAR LYMPHOMA PATIENTS IN MAINTENANCE TREATMENT WITH ANTICD20 MONOCLONAL ANTIBODIES IN SARS-COV2 ERA: RESULTS FROM A MULTICENTER, RETROSPECTIVE- PROSPECTIVE ITALIAN STUDY. | Alessia Castellino | ![]() |
![]() |
|||
1100-P | BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAĎVE MCL (TRIAL IN PROGRESS) | Martin Dreyling | ![]() |
![]() |
|||
1101-P | PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY | Toby A. Eyre | ![]() |
![]() |
|||
1105-P | FINAL RESULTS OF THE PHASE I/II HOVON124/ECWM-R2 STUDY INCLUDING 2-YEAR RITUXIMAB MAINTENANCE AFTER INDUCTION WITH IXAZOMIB, RITUXIMAB AND DEXAMETHASONE IN RELAPSED WALDENSTRÖM´S MACROGLOBULINEMIA | Meletios-Athanasios Dimopoulos | ![]() |
![]() |
|||
1106-P | PRELIMINARY RESULTS OF A PHASE 1 STUDY OF NOVEL BCL-2 INHIBITOR LISAFTOCLAX (APG-2575) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMAS (NHLS) | Mingyuan Sun | ![]() |
![]() |
|||
1107-P | CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+ PTLD WHO FAIL RITUXIMAB PLUS CHEMOTHERAPY: A MULTINATIONAL, RETROSPECTIVE CHART REVIEW STUDY | Ulrich Jaeger | ![]() |
![]() |
|||
1108-P | HIGH COMPLETE RESPONSE RATE FOLLOWING POINT-OF-CARE ANTI CD19 CAR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA | Shalev Fried | ![]() |
![]() |
|||
1110-P | EFFICACY AND SAFETY OF IMMUNOCHEMOTHERAPY IN TREATMENT OF FOLLICULAR NON-HODGKIN´S LYMPHOMA DURING COVID-19 PANDEMIC: A STUDY OF KROHEM, THE CROATIAN COOPERATIVE GROUP FOR HEMATOLOGIC DISEASES | Barbara Dreta | ![]() |
![]() |
|||
1112-P | TREATING BING-NEEL SYNDROME USING A TAILORED APPROACH: EXPERIENCE OF A SPECIALIST NEUROHAEMATOLOGY CLINIC | Jahanzaib Khwaja | ![]() |
![]() |
|||
1114-P | ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI-ARM PHASE 1B STUDY | Jacob D. Soumerai | ![]() |
![]() |
|||
1120-P | THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA | Wenming Chen | ![]() |
![]() |
|||
1122-P | EFFICACY OF ALPELISIB IN PI3K-DRIVEN LANGERHANS CELL HISTIOCYTOSIS | Roei Mazor | ![]() |
![]() |
|||
1123-P | TEMPO: A PHASE 2, RANDOMIZED, OPEN-LABEL, 2-ARM STUDY COMPARING TWO INTERMITTENT DOSING SCHEDULES OF DUVELISIB IN SUBJECTS WITH INDOLENT NON-HODGKIN LYMPHOMA (INHL) | Vladimir Vorobyev | ![]() |
![]() |
|||
1128-P | CLINICAL FEATURES AND OUTCOME OF PATIENTS WITH CASTLEMAN DISEASE: A SPANISH MULTICENTRIC STUDY OF 134 PATIENTS FROM GELTAMO | Jose Tomas Navarro | ![]() |
![]() |
|||
1132-P | PET INTERIM RESULTS PREDICT PROGRESSION-FREE-SURVIVAL IN FOLLICULAR LYMPHOMA PATIENTS WITH ADVANCED STAGE | Maria Poza | ![]() |
![]() |
|||
1133-P | SUB-CUTANEOUS RITUXIMAB INDUCTION FOLLOWED BY SHORT RITUXIMAB MAINTENANCE IMPROVES PFS IN PATIENTS WITH LOW-TUMOR BURDEN FOLLICULAR LYMPHOMA. FINAL RESULTS OF FLIRT PHASE III TRIAL, A LYSA STUDY. | Guillaume Cartron, Md, Phd | ![]() |
![]() |
|||
1134-P | OUTCOMES FOR PATIENTS WITH MANTLE CELL LYMPHOMA POST-CBTK INHIBITOR THERAPY IN THE UNITED STATES AND JAPAN: A STUDY OF TWO REAL-WORLD DATABASES | Shinya Rai | ![]() |
![]() |
|||
1136-P | INTERIM IMAGING DOES NOT PREDICT CLINICAL EVOLUTION IN FOLLICULAR LYMPHOMA IN A REAL-LIFE CLINICAL SETTING | Victoria Ramos De Ascanio | ![]() |
![]() |
|||
1138-P | COPANLISIB + RITUXIMAB VS RITUXIMAB + PLACEBO IN PATIENTS WITH RELAPSED INDOLENT NON-HODGKIN LYMPHOMA (NHL): UPDATED SAFETY AND EFFICACY FROM THE PHASE III CHRONOS-3 TRIAL | Pier Luigi Zinzani | ![]() |
![]() |
|||
1140-P | TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE | Frits Van Rhee | ![]() |
![]() |
|||
1141-P | IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY | Ann Tivey | ![]() |
![]() |
|||
1149-P | THE EVOLVING STATE OF PLAY IN 1000 PATIENTS WITH WALDENSTRÖM´S MACROGLOBULINAEMIA IN THE UNITED KINGDOM (UK): A REAL-WORLD DATA ANALYSIS FROM THE WMUK RORY MORRISON REGISTRY PROJECT | Encarl Uppal | ![]() |
![]() |
|||
1150-P | REAL WORLD DATA ON BORTEZOMIB-BASED THERAPY IN WALDENSTRÖM´S MACROGLOBULINAEMIA: EFFECTIVE EVEN IN MULTIPLY TREATED PATIENTS INCLUDING PRIOR BTK-INHIBITORS | Encarl Uppal | ![]() |
![]() |
|||
1151-P | METABOLIC TUMOR VOLUME IMPROVES OUTCOME PREDICTION IN UNTREATED MANTLE CELL LYMPHOMA | Vibeke Kj Vergote | ![]() |
![]() |
|||
1152-P | RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL) | Ann Maclaren | ![]() |
![]() |
|||
1154-P | STUDY ZILO-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF ZILOVERTAMAB PLUS IBRUTINIB VS IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA | Salim Yazji | ![]() |
![]() |
|||
1155-P | BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM | Yucai Wang | ![]() |
![]() |
|||
1157-P | REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA | Bijal Shah | ![]() |
![]() |
|||
1158-P | REAL-WORLD TREATMENT PATTERNS AND ECONOMIC BURDEN OF PATIENTS WITH MARGINAL ZONE LYMPHOMA | Bijal Shah | ![]() |
![]() |
|||
1160-P | RESULTS OF A PHASE 2 EXPANDED ACCESS STUDY OF ZANUBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA | Jorge J. Castillo | ![]() |
![]() |
|||
1168-P | CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS | Allison Bock | ![]() |
![]() |
|||
1169-P | ELEVATED CRP AT INFUSION OF AXICABTAGENE CILOLEUCEL PREDICTS HIGH-GRADE CAR-T TOXICITY AND OUTPERFORMS MORE COMPLEX SCORES | Stephen Boyle | ![]() |
![]() |
|||
1170-P | INCIDENCE, TREATMENT AND OUTCOME OF PATIENTS WITH RICHTER´S SYNDROME: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS | Mirian Brink | ![]() |
![]() |
|||
1172-P | DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL: UPDATED EXPANSION PHASE ANALYSIS | Pier Luigi Zinzani, Md, Phd | ![]() |
![]() |
|||
1176-P | RITUXIMAB IN PRIMARY CNS LYMPHOMA – LONG TERM FOLLOW-UP OF THE PHASE III HOVON 105/ALLG NHL 24 STUDY | Jeanette Doorduijn | ![]() |
![]() |
|||
1177-P | PROGNOSTIC VALUE OF TP53 VARIANTS IN CHILDREN WITH MATURE B-CELL LYMPHOMA TREATED ACCORDING TO REDUCED-INTENSITY B-NHL-2010M PROTOCOL | Volchkov Egor | ![]() |
![]() |
|||
1180-P | ARE EXTRANODAL LIMITED-STAGE DIFFUSE LARGE B-CELL LYMPHOMA MORE AGRESSIVE THAN NODAL FORMS? | Catarina Fernandes | ![]() |
![]() |
|||
1183-P | CAR-T MORPHOLOGICAL CHARACTERISTICS AND DYNAMICS IN PERIPHERAL BLOOD, EVALUATED BY A NOVEL MICROSCOPY PLATFORM | Gil Fridberg | ![]() |
![]() |
|||
1185-P | ANTITUMOR ACTIVITY AND SAFETY OF ZANUBRUTINIB COMBINED WITH R-CHOP REGIMEN IN THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DLBCL WITH EXTRANODAL INVOLVEMENT: A PROSPECTIVE PHASE II STUDY. | C. Li | ![]() |
![]() |
|||
1187-P | END OF TREATMENT 18F FDG-PET/CT RESPONSE IS PROGNOSTIC FOR OVERALL AND PROGRESSION-FREE SURVIVAL IN PERIPHERAL T-CELL LYMPHOMA: RESULTS OF THE UK NCRI PHASE 2 RANDOMISED CHEMO-T TRIAL PET/CT SUBSTUDY | Mary Gleeson | ![]() |
![]() |
|||
1194-P | A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL) | Tapan Kadia | ![]() |
![]() |
|||
1195-P | A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA. | Matko Kalac | ![]() |
![]() |
|||
1199-P | MACHINE-LEARNING ALGORITHM TO DETECTION OF LYMPHOMA WITH BONE MARROW INVOLVEMENT VIA FDG-18 PET/CT | Cho-Hao Lee | ![]() |
![]() |
|||
1201-P | ZANUBRUTINIB PLUS RCHOP(ZR-CHOP) REGIMEN ACHIEVES HIGH COMPLETE RESPONSE RATE IN THE TREATMENT OF NEWLY-DIAGNOSED DOUBLE-EXPRESSION DIFFUSE LARGE B CELL LYMPHOMA | Zengjun Li | ![]() |
![]() |
|||
1207-P | MULTICENTER RANDOMIZED CONTROLLED (COMPARATIVE) OPEN PROSPECTIVE STUDY TO EVALUATE THE EFFICACY OF THE R-DA-EPOCH-21 AND R-MNHL-BFM-90 ± AUTO- HSCT PROGRAMS IN PATIENTS WITH DE NOVO DIFFUSE B-CELL LAR | Aminat Magomedova | ![]() |
![]() |
|||
1209-P | INCIDENCE, TREATMENT AND OUTCOME OF BREAST IMPLANT-ASSOCIATED ANAPLASTIC LARGE CELL LYMPHOMA: A POPULATION-BASED COHORT STUDY IN THE NETHERLANDS | Frederik O. Meeuwes | ![]() |
![]() |
|||
1220-P | CHARACTERISTICS OF SECONDARY CENTRAL NERVOUS SYSTEM INVOLVEMENT IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA – A SUPPLEMENTARY ANALYSIS OF JCOG0601 | Kazuyuki Shimada | ![]() |
![]() |
|||
1223-P | PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A RETROSPECTIVE STUDY OF THE ZRMA REGIMEN(ZANUBRUTINIB, RITUXIMAB, METHOTREXATE AND CYTARABINE) | Youhong Tang | ![]() |
![]() |
|||
1224-P | EFFICACY OF RITUXIMAB AND BIOSIMILAR RITUXIMAB IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA, A DANISH POPULATION BASED ANALYSIS | Amal Haujir | ![]() |
![]() |
|||
1225-P | SECONDARY PRIMARY MALIGNANCIES (SPM) AFTER HIGH-DOSE CHEMOTHERAPY (HDT) WITH AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR LYMPHOMA: A DANISH NATIONWIDE COHORT STUDY | Trine Trab | ![]() |
![]() |
|||
1227-P | POLATUZUMAB VEDOTIN, RITUXIMAB, AND BENDAMUSTINE COMBINATION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A REAL-WORLD DATA FROM TURKEY | Bahar Uncu Ulu | ![]() |
![]() |
|||
1240-P | ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL | Lei Zhang | ![]() |
![]() |
|||
1246-P | DIFFERENTIAL ROLE OF MICROENVIRONMENT AND STROMAL-CELL INDUCED VENETOCLAX RESISTANCE IN MANTLE CELL LYMPHOMA | Pilar Andersen | ![]() |
![]() |
|||
1250-P | EU-SOX11CCND1: A NOVEL IMMUNOCOMPETENT MURINE MODEL OF MANTLE CELL LYMPHOMA | Fiona Brown | ![]() |
![]() |
|||
1251-P | BONE-BASED 3D SCAFFOLD AS AN IN-VITRO MODEL OF MICROENVIRONMENT-LYMPHOMA INTERACTION | Jessica Ceccato | ![]() |
![]() |
|||
1253-P | MAVORIXAFOR DISRUPTS THE CROSS TALK BETWEEN WALDENSTRMS MACROGLOBULINEMIA CELLS AND THE BONE MARROW MICROENVIRONMENT RESULTING IN ENHANCED SENSITIVITY TO B-CELL TARGETED THERAPIES | Halenya Monticelli | ![]() |
![]() |
|||
1254-P | RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS | Vera De Jonge | ![]() |
![]() |
|||
1255-P | TUMOR-ASSOCIATED MONOCYTIC MYELOID DERIVED SUPPRESSOR CELLS IS A POTENTIAL PROGNOSTIC BIOMARKER, PROMOTING MULTI-DRUG RESISTANCE IN NHL PATIENTS BY MODULATING IL-6/IL-10/IL-1? AXIS | Sukanya Dhar | ![]() |
![]() |
|||
1256-P | A NOVEL DROP-OFF DIGITAL PCR ASSAY FOR CXCR4 MUTATION SCREENING IN IGM GAMMOPATHIES: FIRST DATA FROM THE FONDAZIONE ITALIANA LINFOMI BIO-WM STUDY | Daniela Drandi | ![]() |
![]() |
|||
1259-P | CHARACTERIZATION OF VENETOCLAX RESISTANCE IN CELL MODELS OF MANTLE CELL LYMPHOMA | Agnete Granau | ![]() |
![]() |
|||
1260-P | UNRAVELING THE GENETICS OF TRANSFORMED SPLENIC MARGINAL ZONE LYMPHOMA | Marta Grau | ![]() |
![]() |
|||
1262-P | EZH2 INHIBITORS MEDIATE PLATINUM RESISTANCE BY ENHANCED EFFLUX | Elisabeth Groß | ![]() |
![]() |
|||
1263-P | A SENSITIVE NGS ASSAY TO DETECT MEASURABLE RESIDUAL DISEASE (MRD) IN B-CELL LYMPHOPROLIFERATIVE DISEASES | Presha Shah | ![]() |
![]() |
|||
1264-P | HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY | Simon Husby | ![]() |
![]() |
|||
1267-P | HSP110 FAVORS BCR SIGNALING THROUGH SYK PHOSPHORYLATION IN DIFFUSE LARGE B CELL LYMPHOMA | Vincent Cabaud Gibouin | ![]() |
![]() |
|||
1268-P | DELINEATING THE NEOANTIGEN BURDEN AND TUMOUR MICROENVIRONMENT IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA (DLBCL). | Yanrong Jiang | ![]() |
![]() |
|||
1270-P | IMMUNE REGULATORY CELLS IN B-CELL LYMPHOMAS: SIGNIFICANT HETEROGENEITY ACROSS HISTOLOGIC TYPES. | Christina Kalpadakis | ![]() |
![]() |
|||
1273-P | INVESTIGATING THE ONCOGENIC POTENTIAL OF STAT5BN642H IN NK CELLS | Klara Klein | ![]() |
![]() |
|||
1274-P | EARLY DETECTION OF NON-HODGKIN LYMPHOMA IN PREDISPOSED PATIENT GROUPS THROUGH IMMUNOGENETIC SEQUENCING | Pieter Martijn Kolijn | ![]() |
![]() |
|||
1275-P | PERCENTAGE OF TUMOR INFILTRATING T LYMPHOCYTES MEASURED BY FLOW CYTOMETRY AT DIAGNOSIS PREDICTS SURVIVAL AFTER SALVAGE CHEMOTHERAPY IN RELAPSED/ REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA PATIENTS. | Laura Korin | ![]() |
![]() |
|||
1277-P | MUTATIONAL LANDSCAPE AND COPY NUMBER ALTERATIONS IN TESTICULAR LARGE B-CELL LYMPHOMA | Cristina López | ![]() |
![]() |
|||
1278-P | ACTIVATION OF THE NECROPTOSIS PATHWAY PLAYS A ROLE IN SYNERGISM WITH COMBINATION OF THE IAP ANTAGONIST, TOLINAPANT AND HYPOMETHYLATING AGENTS (HMA) IN IN VITRO MODELS OF T-CELL LYMPHOMA (TCL). | John Sanil Manavalan, Md | ![]() |
![]() |
|||
1279-P | INHIBITION OF PROTEIN KINASE CK2 AND BCL-2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH | Sabrina Manni | ![]() |
![]() |
|||
1282-P | DISEASE-SPECIFIC U1 SPLICEOSOMAL RNA MUTATIONS IN MATURE B-CELL NEOPLASMS | Ferran Nadeu | ![]() |
![]() |
|||
1284-P | LIQUID BIOPSY BY ULTRA-DEEP SEQUENCING PLUS PET-TC MONITORING IN REAL-LIFE FOLLICULAR LYMPHOMA PATIENTS | Ana Jiménez-Ubieto | ![]() |
![]() |
|||
1287-P | DISTINGUISHING BETWEEN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA USING THE LYMPH3CX GENE EXPRESSION PROFILING ASSAY | Ryan S. Robetorye | ![]() |
![]() |
|||
1289-P | COMPUTATIONAL SIMULATIONS SHED LIGHT ON THE 3D CONSEQUENCE OF SUPER-ENHANCER HIJACKING IN B CELL MALIGNANCIES | Lisa Russell | ![]() |
![]() |
|||
1292-P | MOLECULAR CHARACTERIZATION OF DIFFUSE LARGE B-CELL LYMPHOMA ASSOCIATED TO HEPATITIS C VIRUS INFECTION | Roberta Sciarra | ![]() |
![]() |
|||
1295-P | DECIPHERING THE ROLE OF MSI2 AS A REGULATOR OF MANTLE CELL LYMPHOMA STEM-LIKE PROPERTIES | Marta Sureda-Gómez | ![]() |
![]() |
|||
1297-P | ABERRANT MYCN EXPRESSION DRIVES ONCOGENIC HIJACKING OF EZH2 AS A TRANSCRIPTIONAL ACTIVATOR IN PERIPHERAL T CELL LYMPHOMA | Marlies Vanden Bempt | ![]() |
![]() |
|||
1299-P | LOSS OF TYROSINE PHOSPHATASE SHP1 SENSITIZES DLBCL TO IBRUTINIB: A CANDIDATE PREDICTIVE BIOMARKER | Y. Lynn Wang | ![]() |
![]() |
|||
1303-P | POTENTIATING ANTI-CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS | Adrian Wiestner | ![]() |
![]() |
|||
1304-P | THE NOVEL TUMOR SUPPRESSOR SAMHD1 CONTRIBUTES TO ANTI-TUMOR RESPONSES IN A CGAS-STING-DEPENDENT OR INDEPENDENT PATHWAY IN HODGKIN LYMPHOMA (HL) | Ioanna Xagoraris | ![]() |
![]() |
|||
1305-P | HSA_CIRC_0001599 REGULATES IL18 LEVELS IN AGVHD VIA CERNA MECHANISM | Mengting Xia | ![]() |
![]() |
|||
1307-P | TESTING THE IMPORTANCE OF ANTIOXIDANTS ON THE PATHOGENESIS OF B CELL LYMPHOMA | Haidong Yao | ![]() |
![]() |
|||
1310-P | A ROBUST APPROACH FOR THE GENERATION OF FUNCTIONAL HEMATOPOIETIC PROGENITOR CELL LINES TO MODEL LEUKEMIC TRANSFORMATION | Eszter Doma | ![]() |
![]() |
|||
1313-P | PREDICTING OUTCOMES IN AML PATIENTS CONSOLIDATED BY AN ALLOGENEIC STEM CELL TRANSPLANTATION USING THE KNOWLEDGE BANK APPROACH | Madlen Jentzsch | ![]() |
![]() |
|||
1316-P | ASSESSING GENOMIC SAFETY OF ANTIVIRAL NUCLEOSIDE ANALOGS IN HEMATOPOIETIC STEM CELLS | Flavia Peci | ![]() |
![]() |
|||
1317-P | TIME SERIES CLUSTERING OF T CELL SUBSETS DISSECTS HETEROGENEITY IN IMMUNE RECONSTITUTION AND SURVIVAL AMONG RECIPIENTS OF MUD-HCT WITH ATG OR PTCY | Amin Turki | ![]() |
![]() |
|||
1319-P | T AND B LYMPHOCYTES SUBSETS AFTER BNT162B2 ANTI-SARS-COV-2 M-RNA VACCINATION: A COMPARISON BETWEEN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS AND HEALTHY CONTROLS. | Immacolata Attolico | ![]() |
![]() |
|||
1326-P | FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA | Juan Manuel Cerezo-Martin | ![]() |
![]() |
|||
1328-P | SUCCESFUL TREATMENT OF GRAFT FAILURE IN AUTOLOGOUS STEM CELL TRANSPLANTATION WITH CYCLOSPORINE | Damian Cubillas | ![]() |
![]() |
|||
1329-P | POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION. | Francois Dachy | ![]() |
![]() |
|||
1333-P | PLASMA EXCHANGE, IMMUNOGLOBULIN & PRE-TRANSPLANT IMMUNOSUPPRESSION: AN EFFECTIVE DESENSITISATION STRATEGY FOR DSA ALLOANTIBODIES IN HAPLOIDENTICAL HCT FOR PAEDIATRIC RED CELL DISORDERS | Daniel Dexter | ![]() |
![]() |
|||
1334-P | THE IMPACT OF IMMUNOSUPPRESSION ON RECONSTITUTION OF CMV-SPECIFIC T CELLS AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Anna Dmitrova | ![]() |
![]() |
|||
1335-P | SECONDARY MALIGNANCIES AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION. SINGLE HOSPITAL EXPERIENCE. | Andrea Dorado López | ![]() |
![]() |
|||
1342-P | A SCREENING TOOL TO DETECT CHRONIC OCULAR GRAFT VERSUS HOST DISEASE IN A HEMATOLOGY/ ONCOLOGY OUTPATIENT SETTING | Emily Greenan | ![]() |
![]() |
|||
1343-P | TRANSPLANT OUTCOMES OF LYMPHOMA PATIENTS UNDERGOING STEM CELL MOBILIZATION WITH PLERIXAFOR | Ahmet Kursad Gunes | ![]() |
![]() |
|||
1346-P | EVALUATION OF CURRENT NATIONAL PRACTICE IN THE PREVENTION OF PTLD POST PAEDIATRIC HSCT | Iman Sulevani | ![]() |
![]() |
|||
1352-P | THE INTRA-POPULATION HLA DIVERSITY IN CRETE AND THE IMPORTANCE OF THE REGIONAL PUBLIC UMBILICAL CORD BLOOD BANK IN HLA-BASED DONOR SELECTION FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION | Helen Latsoudis | ![]() |
![]() |
|||
1356-P | PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION | Madlen Jentzsch | ![]() |
![]() |
|||
1358-P | WILL COVID-19 PANDEMIC CHANGE MOBILIZATION STRATEGY OF HEMATOPOIETIC STEM CELLS IN MULTIPLE MYELOMA PATIENTS FOR THE BETTER? | Bárbara Marques | ![]() |
![]() |
|||
1359-P | USING GENE-MODIFIED AUTOLOGOUS STEM CELLS PROGENY TO REEDUCATE THE TUMOR IMMUNE MICROENVIRONMENT OF SOLID TUMORS (TEM-GBM STUDY) | Francesca Farina | ![]() |
![]() |
|||
1362-P | FEASIBILITY OF HAEMATOPOIETIC STEM CELL MOBILIZATION AFTER CONSOLIDATION WITH GEMTUZUMAB OZOGAMICIN AND INTERMEDIATE-DOSES ARA-C AND DAUNORUBICIN IN AML | Salvatore Perrone | ![]() |
![]() |
|||
1365-P | DONOR LYMPHOCYTE INFUSION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: RESULTS FROM A RETROSPECTIVE STUDY | D. Rochate | ![]() |
![]() |
|||
1373-P | TACKLING IMMUNOLOGICAL FINDINGS AS SURROGATE MARKERS OF HISTOLOGICAL SEVERITY AND RESPONSE TO THERAPY IN ACUTE GASTROINTESTINAL GRAFT-VERSUS-HOST DISEASE | Mário Sousa-Pimenta | ![]() |
![]() |
|||
1380-P | DEGREE OF CELL PACKING OF CRYOPRESERVED AT -80şC HEMATOPOIETIC STEM CELLS DOES NOT AFFECT THEIR VIABILITY AND HEMATOLOGIC RECOVERY OF TRANSPLANTED MYELOMA PATIENTS | Ivan Tonev | ![]() |
![]() |
|||
1381-P | EARLY FULL DONOR CHIMERISM AFTER FLAMSA RIC BASED ALLOGENEIC HSCT BUT NOT PRESENCE OF MORPHOLOGICAL REMISSION ASSOCIATES WITH OUTCOMES IN R/R AML PATIENTS | Jule Ussmann | ![]() |
![]() |
|||
1383-P | EXTRAMEDULLARY RELAPSE OF ACUTE MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION - A SINGLE-CENTER EXPERIENCE | Francisca Vasconcelos | ![]() |
![]() |
|||
1386-P | A REVIEW OF HEMATOPOIETIC CELL TRANSPLANTATION IN TAIWAN: DATA AND TRENDS DURING 2009–2018 | Yu-Hung Wang | ![]() |
![]() |
|||
1395-P | POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME AFTER PEDIATRIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE-CENTER EXPERIENCE | Suleimen Zhumatayev | ![]() |
![]() |
|||
1396-P | EFFICACY AND SAFETY COMPARISON OF CALCINEURIN INHIBITORS USED FOR GVHD PROPHYLAXIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA | Suleimen Zhumatayev | ![]() |
![]() |
|||
1398-P | INSIGHT INTO ACUTE MYELOID LEUKEMIA INDUCED MSC SECRETOME TO REROUTE THE COURSE OF LEUKEMIA BONE MARROW NICHE | Giulia Borella | ![]() |
![]() |
|||
1405-P | ARGININE-DEPENDENT REGULATION OF THE EUKARYOTIC TRANSLATION INITIATION FACTOR (EIF)5A CONTROLS HUMAN HEMATOPOIETIC PROGENITOR FATE TO THE ERYTHROID LINEAGE | Pedro Gonzalez-Menendez | ![]() |
![]() |
|||
1406-P | TIMING OF EXPOSURE TO INFECTIOUS MICROBIOTA DETERMINES HSC FITNESS | Jeyan Jayarajan | ![]() |
![]() |
|||
1408-P | MONOALLELIC AND BIALLELIC GERMLINE MUTATIONS AFFECTING THE TRANSCRIPTION FACTOR HELIOS CAUSE PLEIOTROPIC DEFECTS OF IMMUNITY | Daniel Mayr | ![]() |
![]() |
|||
1409-P | MACROPHAGES PROVIDE ESSENTIAL SUPPORT FOR ERYTHROPOIESIS DURING CHRONIC PSYCHOLOGICAL STRESS | Sanja Momcilovic | ![]() |
![]() |
|||
1412-P | UNCOUPLING INK4 PROTEINS FROM CDK4/CDK6 IN HEMATOPOIETIC STEM CELLS | Alessia Schirripa | ![]() |
![]() |
|||
1420-P | PRE-CLINICAL PROOF OF CONCEPT DEMONSTRATES ROBUST ACTIVITY OF UCART20X22 DUAL CAR T-CELLS FOR THE TREATMENT OF B-CELL MALIGNANCIES | Beatriz Aranda Orgilles | ![]() |
![]() |
|||
1421-P | BIMODAL TARGETING OF CYTOKINE RECEPTOR-LIKE FACTOR 2 (CRLF2) WITH JAK INHIBITION AND CHIMERIC ANTIGEN RECEPTOR T CELL IMMUNOTHERAPY IN DOWN SYNDROME ACUTE LYMPHOBLASTIC LEUKEMIA | Asen Bagashev | ![]() |
![]() |
|||
1422-P | IN VIVO G-CSF TREATMENT ACTIVATES THE GR-SOCS1 AXIS TO SUPPRESS IFN-G SECRETION BY NATURAL KILLER CELLS | Xiangyu Zhao | ![]() |
![]() |
|||
1423-P | CIRCULATING CELL-FREE DNA KINETICS MEASURED BY DIGITAL PCR IN LYMPHOMA PATIENTS UNDERGOING CD19-CAR-T THERAPY | Miguel López-Esteban | ![]() |
![]() |
|||
1425-P | ACTIVATED AND EXPANDED NATURAL KILLER CELLS TRANSDUCED WITH AN NKG2D CHIMERIC ANTIGEN RECEPTOR AGAINST ACUTE MYELOID LEUKEMIA | Laura Córdoba | ![]() |
![]() |
|||
1426-P | WU-NK-101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML) | Jan Davidson-Moncada | ![]() |
![]() |
|||
1430-P | GUT MICROBIOTA DIVERSITY AND BUTYRATE PRODUCERS IMPACTS ON NON-HODGKIN LYMPHOMA PATIENTS RESPONSE TO CD19 CAR-T THERAPY | Roberto Garcia-Vicente | ![]() |
![]() |
|||
1432-P | THE NOVEL DUAL T/B-CELL SIGNALING MOLECULE CONFERS THE GREATER TUMORICIDAL ACTIVITY AND T-CELL PERSISTENCE OF CD19 CHIMERIC ANTIGEN RECEPTOR T-CELL | Wannakorn Khopanlert | ![]() |
![]() |
|||
1433-P | USE OF A FOAMY-VIRUS VECTOR SYSTEM TO PRODUCE AN ´OFF-THE-SHELF´ ANTI-CD19 CAR T CELL PRODUCT | Ioanna Lazana | ![]() |
![]() |
|||
1434-P | CORRECTION OF CONGENITAL NEUTROPENIA-RELATED GENES IN NAĎVE IPS CELLS DERIVED FROM PATIENTS USING VIRAL-FREE CRISPR/CAS9 GENE-EDITING SYSTEM | Damian Krzyzanowski | ![]() |
![]() |
|||
1445-P | MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE | Viktoria Blumenberg | ![]() |
![]() |
|||
1448-P | LONG-TERM SURVIVORS AFTER FAILURE OF CAR-T CELL THERAPY FOR R/R LARGE B-CELL LYMPHOMA (LBCL): A GLA/DRST STUDY | Patrick Derigs | ![]() |
![]() |
|||
1456-P | EARLY SAFETY AND CLINICAL COURSE OF PATIENTS WITH ACUTE MYELOID LEUKEMIA AND MEASURABLE RESIDUAL DISEASE RECEIVING GTA002, AN OFF-THE-SHELF, EX VIVO-CULTURED ALLOGENEIC NK CELL PREPARATION | Michael Heuser | ![]() |
![]() |
|||
1457-P | DEMOGRAPHICS AND TREATMENT OUTCOMES IN PATIENTS WITH EBV+ PTLD TREATED WITH OFF-THE-SHELF EBV-SPECIFIC CTL (TABELECLEUCEL) UNDER AN ONGOING EXPANDED ACCESS PROGRAM IN EUROPE: FIRST ANALYSES | Daan Dierickx | ![]() |
![]() |
|||
1461-P | CAR-T VS. STANDARD OF CARE AS SECOND LINE TREATMENT FOR LARGE B CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS | Liat Shargian | ![]() |
![]() |
|||
1462-P | POPULATION-BASED REAL WORLD RESULTS OF CD19-DIRECTED CAR T-CELL THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: A DUTCH CAR T-CELL TUMORBOARD EXPERIENCE | Anne Mea Spanjaart | ![]() |
![]() |
|||
1464-P | DECREASING HPK1 EXPRESSION IN CD19 CAR-T CELLS: A NOVEL STRATEGY TO OVERCOME CHALLENGES OF CELL THERAPY FOR ADULT (R/R) B-ALL | Guangxun Gao | ![]() |
![]() |
|||
1470-P | NATURAL HISTORY AND RATE OF PROGRESSION OF RETINOPATHY IN PATIENTS WITH SICKLE CELL DISEASE: AN 11-YEAR RETROSPECTIVE FOLLOW-UP ANALYSIS | Rajani Brandsen | ![]() |
![]() |
|||
1471-P | CURRENT INDICATIONS AND RISKS OF SPLENECTOMY IN A LARGE MODERN COHORT OF CHILDREN WITH SCA | Valentine Brousse | ![]() |
![]() |
|||
1474-P | MOLECURAL MECHANISM OF CHEMOTHERAPEUTIC HYDROXYUREA IS MEDIATED BY NOS2 | Teodora Dragojevic | ![]() |
![]() |
|||
1479-P | A BASELINE AUDIT OF THE USE A VALIDATED PSYCHOMETRIC TOOL (ASCQ-ME) TO ASSESS THE UNMET PSYCHOLOGICAL NEEDS OF A 2021 COHORT OF PATIENTS LIVING WITH SICKLE CELL | Kyle Kelleher | ![]() |
![]() |
|||
1480-P | SPLENIC SEQUESTRATION IS MORE COMMON IN SCD-S/?0-THAL THAN IN SCD-S/S PATIENTS: RESULTS FROM THE GERMAN SCD REGISTRY | Joachim Kunz | ![]() |
![]() |
|||
1492-P | PHARMACODYNAMIC EFFECTS OF AG-946, A HIGHLY POTENT NOVEL ACTIVATOR OF PYRUVATE KINASE, IN EX VIVO TREATMENT OF RED BLOOD CELLS FROM SICKLE CELL DISEASE PATIENTS | Minke Rab | ![]() |
![]() |
|||
1493-P | CHRONIC COMPLICATIONS IN THE EAST LONDON SICKLE NEWBORN COHORT STUDY (ELSNCS) | Muriel Soriano | ![]() |
![]() |
|||
1494-P | INDICATIONS OF HEMATOPOIETIC STEM CELL TRANSPLANT ACCORDING TO DIFFERENT SETS OF INDICATIONS AND ANALYSIS OF COMORBIDITY INDEX SCORES IN BRAZILIAN PATIENTS WITH SICKLE CELL DISEASE | Gabrielle Santos | ![]() |
![]() |
|||
1500-P | 2,3-DIPHOSPHOGLYCERATE DETECTION VIA DIRECT INFUSION HIGH RESOLUTION MASS SPECTROMETRY CORRELATES WITH QUANTITATIVE DETECTION IN BLOOD OF PATIENTS WITH SICKLE CELL DISEASE | S. Van Der Veen | ![]() |
![]() |
|||
1501-P | FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE | Myrthe J. Van Dijk | ![]() |
![]() |
|||
1502-P | LONG-TERM FOLLOW-UP OF DUTCH PATIENTS WITH SICKLE CELL DISEASE DIAGNOSED BY NEONATAL SCREENING – EFFECT ON THE MORBIDITY AND MORTALITY IN THE NETHERLANDS. | Caroline Vuong | ![]() |
![]() |
|||
1503-P | REAL WORLD DATA ON EFFICACY OF PHARMACEUTICAL-GRADE L-GLUTAMINE IN PREVENTING SICKLE CELL DISEASE-RELATED ACUTE COMPLICATIONS AND HEMOLYSIS IN PEDIATRIC AND ADULT PATIENTS. | Mohamed Yassin | ![]() |
![]() |
|||
1504-P | AN AUDIT OF PAIN EDUCATION IN PATIENTS WITH SICKLE CELL DISEASE | Yuhui Zhou | ![]() |
![]() |
|||
1505-P | USING ARTIFICIAL INTELLIGENCE NEURAL NETWORKS TO OBTAIN AUTOMATED LIVER IRON CONCENTRATION MEASUREMENTS USING MAGNETIC RESONANCE IMAGING – A MULTI-SCANNER VALIDATION STUDY | Tim St Pierre | ![]() |
![]() |
|||
1506-P | REAL-WORLD DATA ON THE USE OF LUSPATERCEPT IN GREEK PATIENTS WITH TRANSFUSION DEPENDENT THALASSEMIA | Polyxeni Delaporta | ![]() |
![]() |
|||
1511-P | EFFICACY AND SAFETY OF COMBINATION IRON CHELATION THERAPY WITH DEFERIPRONE AND DEFERASIROX IN PATIENTS WITH ?-THALASSEMIA MAJOR: A SYSTEMATIC LITERATURE REVIEW | Antonio Piga | ![]() |
![]() |
|||
1512-P | HEART FAILURE IN THALASSEMIA MAJOR: TIME FOR NEW CARDIOVASCULAR MAGNETIC RESONCE MARKERS? | Antonella Meloni | ![]() |
![]() |
|||
1513-P | LOW VITAMIN D LEVELS ARE ASSOCIATED WITH INCREASED CARDIAC IRON UPTAKE IN THALASSEMIA MAJOR. | Antonella Meloni | ![]() |
![]() |
|||
1514-P | MULTI-PARAMETRIC CARDIAC MAGNETIC RESONANCE FOR RISK PREDICTION OF HEART FAILURE DEATH IN THALASSEMIA MAJOR | Antonella Meloni | ![]() |
![]() |
|||
1515-P | IMPACT OF GENOTYPE ON PANCREATIC IRON OVERLOAD AND IMPAIRED GLUCOSE METABOLISM IN THALASSEMIA MAJOR | Antonella Meloni | ![]() |
![]() |
|||
1525-P | MANAGEMENT OF AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING PREGNANCY OR POST-PARTUM: AN INTERNATIONAL MULTI-CENTRE EXPERIENCE. | Marta Bortolotti | ![]() |
![]() |
|||
1526-P | AUTOIMMUNE HEMOLYTIC ANEMIAS: RELATIONSHIP BETWEEN SINGLE NUCLEOTIDE POLYMORPHISMS OF CYTOKINE GENES AND CLINICAL/HEMATOLOGICAL PARAMETERS | Bruno Fattizzo | ![]() |
![]() |
|||
1527-P | NEXT GENERATION SEQUENCING IN HEREDITARY SPHEROCYTOSIS DIAGNOSIS | Ana García Feria | ![]() |
![]() |
|||
1529-P | HEMOGLOBIN RESPONSE TO ZINC SUPPLEMENTATION IN PATIENTS WITH ZINC DEFICIENCY AND CHRONIC ANEMIA | Zachary Hanson | ![]() |
![]() |
|||
1530-P | PERITRANFUSIONAL C1-INHIBITOR IN PATIENTS WITH SEVERE COMPLEMENT-MEDIATED AUTOIMMUNE HEMOLYTIC ANEMIA: AN OPEN LABEL PHASE 2 TRIAL. | Marit Jalink | ![]() |
![]() |
|||
1531-P | HETEROGENEITY OF DISEASE-CAUSING GENOTYPES BETWEEN FAMILIES WITH HEREDITARY SPHEROCYTOSIS: A SINGLE-CENTER COHORT STUDY | Raul Jimenez Heredia | ![]() |
![]() |
|||
1537-P | HEREDITARY ANEMIA CAUSED BY MULTILOCUS INHERITANCE OF PIEZO1, SLC4A1 AND ABCB6 MUTATIONS: A DIAGNOSTIC AND THERAPEUTIC CHALLENGE. | Barbara Eleni Rosato | ![]() |
![]() |
|||
1540-P | STUDY OF MIRNA EXPRESSION PROFILES IN GAUCHER PATIENTS AND THEIR RELATIONSHIP WITH THE SEVERITY OF BONE INVOLVEMENT | Irene Serrano-Gonzalo | ![]() |
![]() |
|||
1541-P | PRELIMINARY RESULTS OF TWO YEARS FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS TREATED WITH ELIGLUSTAT IN TRAZELGA PROJECT. | Irene Serrano-Gonzalo | ![]() |
![]() |
|||
1549-P | NOVEL SLC4A1 GENE MUTATIONS IN HEREDITARY SPHEROCYTOSIS BAND 3 PROTEIN-DEFICIENT TUNISIAN PATIENTS | Nawel Trabelsi | ![]() |
![]() |
|||
1552-P | A PHASE 2, OPEN-LABEL STUDY TO ASSESS SAFETY, TOLERABILITY, AND CLINICAL EFFECT OF ANX005 IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA AND EVIDENCE OF COMPLEMENT ACTIVATION | Ulrich Jaeger | ![]() |
![]() |
|||
1554-P | INCREASED PREVALENCE OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH CONGENITAL DYSERYTHROPOIETIC ANEMIA TYPE I | Mahdi Asleh | ![]() |
![]() |
|||
1555-P | IRON CHELATION THERAPY IN CONGENITAL HEMOLYTIC ANEMIAS: AN ITALIAN SINGLE CENTER STUDY | Alessandro Bosi | ![]() |
![]() |
|||
1559-P | DISC-0974, A FIRST-IN-HUMAN ANTI-HEMOJUVELIN MONOCLONAL ANTIBODY, REDUCES SERUM HEPCIDIN LEVELS AND MOBILIZES IRON IN HEALTHY PARTICIPANTS | Will Savage, Md, Phd | ![]() |
![]() |
|||
1560-P | IMR-261, A NOVEL, ORAL NRF2 ACTIVATOR, REDUCES IRON OVERLOAD IN AN EXPERIMENTAL MOUSE MODEL BY ACTIVATING BMP6-MEDIATED HEPCIDIN SYNTHESIS | Thiago Trovati Maciel | ![]() |
![]() |
|||
1561-P | IS IRON OVERLOAD ASSOCIATED WITH WORSE OUTCOMES IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING LIVER TRANSPLANT? | Sergio Rodriguez-Rodriguez | ![]() |
![]() |
|||
1566-P | PROTON PUMP INHIBITION FOR SECONDARY HEMOCHROMATOSIS IN HEREDITARY ANEMIA, A PHASE III PLACEBO-CONTROLLED RANDOMIZED CROSS-OVER CLINICAL TRIAL | A.J. Van Vuren | ![]() |
![]() |
|||
1568-P | EARLY, BUT NOT LATE USE OF REMDESVIR AND CONVALESCENT PLASMA REDUCES MORTALITY OF COVID 19 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES – A STUDY OF KROHEM | Igor Aurer | ![]() |
![]() |
|||
1569-P | COVID19 AND ITS IMPACT ON HEMATO-ONCOLOGICAL PATIENTS. DIFFERENCES IN OUTCOMES IN RELATION TO OMICRON CIRCULATION AND VACCINATION STATUS? | Matilde Boada | ![]() |
![]() |
|||
1571-P | EVALUATION OF THE CLINICAL IMPACT OF BONE MARROW CULTURES IN CURRENT MEDICAL PRACTICE | Gal Sharvit | ![]() |
![]() |
|||
1577-P | RISK FACTORS FOR MORTALITY IN CRITICALLY ILL PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A POLYVALENT INTENSIVE CARE UNIT: A RETROSPECTIVE STUDY | Ana Raquel Dias | ![]() |
![]() |
|||
1584-P | CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS | Ronit Gurion | ![]() |
![]() |
|||
1587-P | IS IT SAFE FOR OUR PATIENTS TO COME OUT? | Magda Jabbar Al-Obaidi | ![]() |
![]() |
|||
1588-P | A SINGLE CENTER COMPARATIVE CLINICAL ANALYSIS OF THE SARS-COV-2 INFECTION BEFORE AND AFTER VACCINATION IN PATIENTS DIAGNOSED WITH HEMATOLOGIC MALIGNANCIES | Moraima Jiménez | ![]() |
![]() |
|||
1591-P | HIGH RISK OF BLOOD STREAM INFECTION OF CRE CARRIERS IN NEUTROPENIC CHILDREN WITH HEMATOLOGICAL DISEASES | Li-Peng Liu | ![]() |
![]() |
|||
1596-P | PREDIAGNOSTIC ANTIMICROBIAL USE IN CLL, MM, FL AND DLBCL | Esben Munk Packness | ![]() |
![]() |
|||
1597-P | THE DYNAMIC INTERACTION BETWEEN INFLAMMATION AND IRON SENSORS IN MALARIA-INDUCED ANEMIA | Ana Pęgo | ![]() |
![]() |
|||
1601-P | THE ASSESSMENT OF PREDICTIVE ROLE OF PROTEIN C AND S FOR CRITICAL FORM OF COVID-19 | Viola Popov | ![]() |
![]() |
|||
1602-P | THE ASSESSMENT OF LYMPHOPENIA AS RISK FACTOR FOR UNFAVORABLE EVOLUTION OF PATIENTS WITH SEVERE FORM OF COVID 19 | Viola Popov | ![]() |
![]() |
|||
1605-P | OUTCOME OF SARS-COV-2 INFECTION IN HAEMATOLOGICAL CANCER PATIENTS (PTS) IN TWO DIFFERENT PANDEMIC PHASES AT A SINGLE CENTRE | Raquel Rodrigues | ![]() |
![]() |
|||
1606-P | CENTRAL VEIN CATHETERISATION IN ONCOHEMATOLOGICAL PATIENTS: COMPLICATION, ASSOCIATED WITH PROCEDURA AND CARE | Nikolay Romanenko | ![]() |
![]() |
|||
1607-P | EPICOVIDEHA KIDS: A READY TO USE PLATFORM FOR EPIDEMIOLOGICAL STUDIES IN PEDIATRIC HEMATOLOGICAL PATIENTS WITH COVID-19 | Jon Salmanton-García | ![]() |
![]() |
|||
1608-P | EXPERIENCE AND COMPLICATIONS WITH THE USE OF PICCS IN HEMATOLOGIC PATIENTS | Laura Sanchez-Paz | ![]() |
![]() |
|||
1609-P | VERY LOW MORTALITY IN DOUBLE VACCINATED IMMUNOCOMPROMISED HAEMATOLOGY PATIENTS INFECTED WITH SARS-COV-2. | Briony Shaw | ![]() |
![]() |
|||
1610-P | IMPACT OF COVID-19 ON PATIENTS TREATED WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION - A RETROSPECTIVE COHORT STUDY | Thomas Silfverberg | ![]() |
![]() |
|||
1614-P | MOLECULAR EPIDEMIOLOGY OF INFLUENZA VIRUS IN PATIENTS WITH HEMATOLOGIC DISORDERS | Silan Ünal | ![]() |
![]() |
|||
1618-P | CLINICAL OUTCOME OF COVID-19 CONVALESCENT PLASMA TRANSFUSION IN CHRONIC KIDNEY DISEASE PATIENTS ON RENAL REPLACEMENT THERAPY WITH SEVERE TO CRITICAL COVID-19 DISEASE | Janelle Ahorro | ![]() |
![]() |
|||
1622-P | ANTIPHOSPHOLIPID ANTIBODIES IN CONVALESCENT PLASMA OF DONORS RECOVERED FROM MILD COVID-19 | Dorit Blickstein | ![]() |
![]() |
|||
1626-P | MANAGEMENT OF POST-TRANSFUSION COMPLICATIONS IN PATIENTS WITH HEMATOLOGICAL DISEASES. PREVENTION IS BETTER THAN CURE–DATA FROM A SINGLE INSTITUTION | Yonka Lazarova | ![]() |
![]() |
|||
1627-P | EXPERIENCE OF THE USE OF CONVALESCENT PLASMA FOR THE MANAGEMENT OF COVID 19 IN PATIENTS WHO REQUIRED HOSPITALIZATION IN QUITO-ECUADOR, HOSPITAL METROPOLITANO, DURING THE 2020 PERIOD | Johanna Rojas | ![]() |
![]() |
|||
1629-P | ADMINISTRATION OF CONVALESCENT PLASMA FOR THE TREATMENT OF SEVERE COVID-19: RESULTS OF A MULTICENTER PHASE II TRIAL | Thomas Thomopoulos | ![]() |
![]() |
|||
1632-P | PROSPECTIVE OBSERVATIONAL STUDY IN PATIENTS WITH IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) TREATED WITH TPO-R AGONISTS (TPO-RA): ELTROMBOPAG (EPAG) AND ROMIPLOSTIM (ROMI) - THE PEPITE STUDY | Stéphane Chčze | ![]() |
![]() |
|||
1636-P | PATIENT PREFERENCES AND EXPERIENCES REGARDING THROMBOPOIETIN-RECEPTOR AGONISTS FOR IMMUNE THROMBOCYTOPENIA IN THE NETHERLANDS (TRAPEZE NL STUDY). | A.J. Gerard Jansen | ![]() |
![]() |
|||
1639-P | UTILITY OF NEXT GENERATION SEQUENCING TECHNIQUES TO EVALUATE POSSIBLE CAUSES OF REFRACTORINESS TO TREATMENT WITH ELTROMBOPAG IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN SPAIN. | Tomas Jose Gonzalez-Lopez | ![]() |
![]() |
|||
1644-P | NOVEL VARIANTS IN GALE CAUSED SYNDROMIC MACROTHROMBOCYTOPENIA DISRUPTING THROMBOPOIESIS AND GLYCOSYLATION | Ana Marin Quilez | ![]() |
![]() |
|||
1647-P | CONTRIBUTION OF NEXT GENERATION FLOW (NGF) CYTOMETRY IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP): UTILITY FOR THE DIFFERENTIAL DIAGNOSIS WITH MYELODYSPLASTIC SYNDROMES | Tomas Jose Gonzalez-Lopez | ![]() |
![]() |
|||
1649-P | GFI1B AND LSD1 REPRESS A MYELOID DIFFERENTIATION PROGRAM DURING INDUCED PLURIPOTENT STEM CELL DERIVED MEGAKARYOCYTE DIFFERENTIATION | Jeron Venhuizen | ![]() |
![]() |
|||
1653-P | CLINICAL EFFICACY AND SAFETY OF SWITCHING ELTROMBOPAG AND RH-TPO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA DURING THE COVID-19 PANDEMIC | Xuan Cai | ![]() |
![]() |
|||
1659-P | UNIQUE GENOTYPE-PHENOTYPE RELATIONSHIP IN VON WILLEBRAND DISEASE: A SINGLE CENTRE EXPERIENCE | Mohamed Elshinawy | ![]() |
![]() |
|||
1663-P | THE EFFECTS OF OBESITY ON BLEEDING FREQUENCY AND PARAMETERS OF FIBRINOLYSIS IN PATIENTS WITH NON-SEVERE HEMOPHILIA | Oliver Königsbrügge | ![]() |
![]() |
|||
1664-P | IMPACT OF A PROTOCOL USING RITUXIMAB FOR PREVENTION OF RELAPSE IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP) | Elena Marín Sánchez | ![]() |
![]() |
|||
1669-P | AUTOANTIBODY-MEDIATED PLATELET DESIALYLATION IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA | Theresa Schramm | ![]() |
![]() |
|||
1673-P | THROMBOTIC COMPLICATIONS IN MERS-COV COMPARED TO COVID-19 | Abdulrahman Al Raizah | ![]() |
![]() |
|||
1674-P | CLINICAL IMPACT OF NON-ADHERENCE TO HIT GUIDELINES: A DOUBLE HIT IN HIT | Abdulrahman Al Raizah | ![]() |
![]() |
|||
1681-P | FXI LEVELS AS INDEPENDENT RISK FACTOR FOR THROMBOSIS/OBSTETRIC EVENTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES | María Eugenia De La Morena-Barrio | ![]() |
![]() |
|||
1682-P | MTHFR C677T GENOTYPE IN CORRELATION WITH THROMBOSIS AND ASSOCIATION WITH FVIII COAGULANT ACTIVITY IN GREEK PAEDIATRIC POPULATION | Athina Dettoraki | ![]() |
![]() |
|||
1684-P | NO INCREASE IN THROMBIN GENERATION OR D-DIMER LEVELS AFTER ANTI-SARS-COV-2 VACCINES INCLUDING IN THOSE WITH ANTI-PLATELET FACTOR 4 ANTIBODIES | Lamya Garabet | ![]() |
![]() |
|||
1690-P | NEUTROPHIL EXTRACELLULAR TRAP (NET) LEVELS IN COVID-19 PATIENTS | Laura López De Frutos | ![]() |
![]() |
|||
1692-P | PREDICTIVE MODEL FOR VEIN THROMBOEMBOLIC EVENTS DEVELOPMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA | Mirjana Mitrovic | ![]() |
![]() |
|||
1693-P | THROMBOMODULIN RESISTANCE: A NEW PROTHROMBOTIC PATHWAY IN COVID-19 | Adrián Montańo | ![]() |
![]() |
|||
1695-P | CEREBRAL VENOUS THROMBOSIS AND ANTITHROMBOTIC THERAPY: A SYSTEMATIC REVIEW | Vaia Papageorgiou | ![]() |
![]() |
|||
1697-P | EVALUATION OF THE DIAGNOSTIC PERFORMANCE OF THE TINA-QUANT D-DIMER GEN. 2 IN PATIENTS WITH SUSPECTED DEEP VEIN THROMBOSIS | Brita Tonne | ![]() |
![]() |
|||
1698-P | INCREASED COMPLEMENT ACTIVATION AND DECREASED ADAMTS13 ACTIVITY IN PATIENTS WITH PRE-ECLAMPSIA COMPARED TO HEALTHY PREGNANCIES | Theodora Maria Venou | ![]() |
![]() |
|||
1701-P | A COMPARATIVE STUDY OF THE IMPACT OF COUNTRIES´ HEALTH EXPENDITURE ON THE DIAGNOSIS EXPERIENCES OF PATIENTS WITH LYMPHOMA AND CLL IN EUROPE | Funmi Bamigbola | ![]() |
![]() |
|||
1702-P | IMPACT OF CENTER CHARACTERISTICS AND MACROECONOMIC FACTORS ON THE OUTCOME OF ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH PEDIATRIC-INSPIRED PROTOCOLS | Pere Barba | ![]() |
![]() |
|||
1706-P | CLINICAL UTILITY OF ONLINE MONITORING OF PATIENT-REPORTED SYMPTOMS IN NEWLY DIAGNOSED PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN REAL-LIFE PRACTICE | Fabio Efficace | ![]() |
![]() |
|||
1708-P | PREGNANCIES IN YOUNG ADULTS WITH A HISTORY OF ACUTE LYMPHOBLASTIC LEUKEMIA IN ITALY. A CAMPUS ALL SURVEY. | Fabio Giglio | ![]() |
![]() |
|||
1709-P | FERTILITY PRESERVATION FOR YOUNG ADULT ACUTE LYMPHOBLASTIC LEUKEMIAS IN ITALY: A CAMPUS ALL SURVEY. | Fabio Giglio | ![]() |
![]() |
|||
1716-P | REGULAR HOSPITAL VISITS IMPROVE THE PROGNOSIS OF MULTIPLE MYELOMA PATIENTS | Xiaozhe Li | ![]() |
![]() |
|||
1718-P | A PROSPECTIVE MULTICENTER SURVEY ABOUT THE USE OF NEW TECHOLOGIES AND DIGITAL HEALTH TOOLS IN PATIENTS (PTS) WITH HEMATOLOGICAL MALIGNANCIES | Alberto Lopez-Garcia | ![]() |
![]() |
|||
1719-P | A PATIENT ADVOCACY PERSPECTIVE ABOUT CHRONIC MYELOID LEUKEMIA INEQUITIES IN ACCESS TO THERAPIES AND PATIENT JOURNEY IN THE LATIN AMERICAN REGION. | Jose Luis Castro Aguilar | ![]() |
![]() |
|||
1721-P | PROGNOSTIC FACTORS IN PATIENTS IN THE TERMINAL PHASE OF HEMATOLOGICAL MALIGNANCIES WHO RECEIVED HOME MEDICAL CARE | Naohiro Miyashita | ![]() |
![]() |
|||
1725-P | OBSERVATIONAL STUDY TO EVALUATE PATIENT-REPORTED OUTCOMES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Esther Natalie Oliva | ![]() |
![]() |
|||
1728-P | THE FUTURE OF MYELODYSPLASTIC SYNDROME – PATIENT PRIORITIES AND OUTCOMES THAT MATTER | Matthew Poynton | ![]() |
![]() |
|||
1729-P | COMPARING THE PSYCHOSOCIAL IMPACTS OF THE COVID-19 PANDEMIC BETWEEN HAEMATOLOGICAL CANCER AND MYELOMA PATIENTS: FINDINGS FROM AN ONLINE SURVEY | Stephen James Quinn | ![]() |
![]() |
|||
1730-P | IMPLEMENTATION OF PRO-CTCAE QUESTIONNAIRE IN PROM PROGRAM COLLECTS DIFFERENT ADVERSE EVENTS PROFILE THAN PHYSICIANS AND REDUCE UNSCHEDULED HEALTHCARE IN PATIENTS WITH LYMPHOMA RECEIVING IV THERAPY | Sergio Ramos | ![]() |
![]() |
|||
1733-P | NON-HEMATOLOGICAL MALIGNANCIES IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE PATIENTS: A MATCHED COHORT ANALYSIS USING A HEALTH CLAIMS-BASED DATASET | Sudipto Mukherjee | ![]() |
![]() |
|||
1734-P | LESSONS FROM HIV- HAEMOPHILIA CRISIS AND CURRICULAR LEARNING IN POST COVID TIMES | Mallika Sekhar | ![]() |
![]() |
|||
1746-P | LONG-TERM NON-HODGKIN LYMPHOMA SURVIVORS IN CÔTE D´OR: HEALTH-RELATED QUALITY OF LIFE AND LIVING CONDITIONS. | Stephane Wasse | ![]() |
![]() |
June 9-12 Vienna
![]() |
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. ![]() To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. ![]() |
![]() |
||
![]() |
|